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Type 2 diabetes mellitus (DM) is a disease characterized by hyperglycemia 
due to insulin resistance and insufficiency, constituting 85-90 % of all DM cases. 
There is growing evidence suggesting that cytokine-induced inflammation is likely 
involved in the pathogenesis of type 2 DM and associated with a lot of morbid 
complications such as nephropathy. Diabetic nephropathy，with a prevalence of 40% 
in diabetic patients, is currently the leading cause of end-stage renal disease. 
However, the immunopathogenesis of diabetic nephropathy is not well understood. 
In the present study, we investigated the plasma concentrations and ex vivo 
production of cytokines, chemokines, soluble costimulatory molecules and soluble 
adhesion molecules, as well as the activation of intracellular signaling molecules, 
mitogen activated protein kinases (MAPK), in T helper (Th) cells and monocytes, in 
94 type 2 diabetic patients with or without nephropathy and 20 healthy controls, by 
immunofluorescence flow cytometry and enzyme-linked immunosorbent assay 
(ELISA). 
For inflammatory cytokines and chemokines, plasma concentrations of 
tumour necrosis factor (TNF)-a, interleukin (IL)-6, IL-18 and CCL2 in patients with 
diabetic nephropathy (DN) were significantly higher than in control subjects (all P < 
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0.05), while IL-10, CXCL8，CXCL9, CXCLIO and adiponectin concentrations of 
DN patients were significantly higher than those of patients without diabetic 
nephropathy (NDN) and control subjects (all P < 0.05). Plasma concentrations of 
TNF-a, IL-6，IL-10, IL-18, CCL2, CXCL8，CXCL9, CXCLIO and adiponectin 
exhibited significantly positive correlations with urine albumin: creatinine ratio 
(UACR) in DN patients (all P < 0.05). The % increases of ex vivo production of 
IL-6, CXCL8, CXCLIO, CCL2 and CCL5 upon TNF-a activation were significantly 
higher in both NDN and DN patients than in controls (all P < 0.05), while the % 
increases of ex vivo production of TNF-a and CXCL8 upon IL-18 activation were 
significantly higher in NDN patients than controls (all P < 0.05). 
For T lymphocyte costimulatory molecules, plasma soluble cytotoxic T 
lymphocyte-associated antigen-4 (sCTLA-4) was significantly lower but soluble 
CD28 (sCD28) was significantly higher in DN patients than in controls (all P < 0.05). 
Plasma concentrations of sCD28，sCD80 and sCD86 were positively correlated with 
UACR in DN patients (all P < 0.05). The % increases of ex vivo production of 
sCTLA-4 and sCD28 were significantly higher in DN patients than in NDN patients 
and controls upon TNF-a activation (all P < 0.05)，and in controls upon IL-18 
activation (all P < 0.05). However, the % increases of ex vivo production of sCD80 
upon TNF-a activation was significantly lower in DN patients than in both NDN 
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patients and controls {P < 0.001). 
For soluble adhesion molecules, plasma concentrations of soluble 
intercellular adhesion molecules (sICAM)-l, sICAM-3, soluble platelet-endothelial 
cell adhesion molecule-1 (sPECAM-1) and sE-selectin in DN patients were 
significantly higher than in control subjects, while soluble vascular cellular adhesion 
molecules-1 (sVCAM-1) and sP-selectin concentrations in both DN and NDN 
patients were significantly higher than in control subjects (all P < 0.05). sPECAM-1 
and sVCAM-1 concentrations of DN patients were significantly higher than those of 
NDN patients (all P < 0.05). Plasma concentrations of sVCAM-1 and sP-selectin 
were significantly positively correlated with UACR in DN patients (all P < 0.05). 
For intracellular signaling molecules, the % increases in IL-18-induced 
phosphorylation of extracellular signal-regulated kinase (ERK) in Th cells of NDN 
and DN patients were significantly higher than controls (all P < 0.05)，while the % 
increase in TNF-a-induced phosphorylation of p38 MAPK in monocytes and 
IL-18-induced phosphorylation of p38 MAPK in Th cells and monocytes were 
significantly higher in NDN patients than controls (all P < 0.05). The TNF-a and 
IL-18 induced phosphorylations of c-Jun NH2-terminal kinase (JNK) in Th cells and 
monocytes were found to be similar to that of p38 MAPK. 
These results confirmed that the aberrant production of 
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inflammation-related molecules and differential activation of MAPK in different 
leukocytes were the underlying immunopathological mechanisms of type 2 DM and 
diabetic nephropathy. 
Since previous studies have reported that both plasma and urinary TNF-a 
concentrations were markedly increased in patients with diabetic nephropathy, we 
conducted an in vitro study to investigate the effect of TNF-a on the expression of 
cytokines, chemokines and cell surface adhesion molecules on human proximal 
tubular epithelial cells, Human Kidney (HK)-2 cells, and the underlying intracellular 
MAPK regulatory signaling mechanisms by flow cytometry and ELISA. 
Our results demonstrated that TNF-a could significantly induce chemokine 
CCL2, adhesion molecules ICAM-1 and VCAM-1 expression of HK-2 cells. 
Selective inhibitors of p38 MAPK (SB203580), INK (SP600125) and ERK 
(PD98059) could suppress TNF-a-induced CCL2 and ICAM-1 expression, while 
only p38 MAPK and ERK inhibitors could suppress TNF-a-induced VCAM-1 
expression. JNK inhibitor was found to upregulate VCAM-1 expression but did not 
elicit any additive effect with TNF-a on VCAM-1 expression. Therefore, TNF-a 
could play a crucial role in macrophage and lymphocyte infiltration in nephritis by 
inducing CCL2, ICAM-1 and VCAM-1 expression via the activation of the 













蛋白激畴 ( M A P K )的活性。 
從炎症細胞因子和趨化因子的研究結果顯示，糖尿病賢炎患者（DN組） 
血毁中的腫瘤壞死因子 - a ( T N F - a ) � 白介素（ I L ) - 6 � I L - 1 8 和 C C L Z 比健康 
對照者明顯地高（全部戶〉0. 05)，而他們血毁中的IL-10�CXCL8�CXCL9�CXCL10 
和脂聯素則比普通糖尿病患者（N D N組）和健康對照者高（全部尸〉0 . 0 5 ) ° 
在 DN 組裡，T N F - a � I L - 6 � I L - 1 0 � I L - 1 8 � C C L 2 � C X C L 8 � C X C L 9 � C X C L 1 0 和 
脂聯素的表達都與尿白蛋白••肌酸酐比值（IIACR)呈正相關（全部尸〉0.05)� 
於T N F - a的刺激下，D N組的 I L - 6 � C X C L 8 � C X C L 1 0 � C C L 2和C C L 5離體增產率 
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比NDN組和健康對照者較高（全部尸〉0. 05 )；而在 IL -18的刺激下，DN組的 
T N F - a和C X C L 8離體增產率都比N D N組和健康對照者較高（全部> 0. 0 5 ) � 
至於可溶性T淋巴細胞共同激發分子的研究，我們發現DN組的血裝含 
有的可溶性細胞毒T淋巴細胞相關抗原 - 4 ( sCTLA-4)比健康對照者低，但所 
含的可溶性白細胞分化抗原2 8 ( s C D 2 8 )比健康對照者高（全部户〉 0 . 0 5 ) � 
在D N組裡，S C D 2 8 �可溶性白細胞分化抗原8 0 ( sCD80)和可溶性白細胞分化 
抗原8 6 ( S C D 8 6 )的表達都與U A C R呈正相關（全部户〉 0 . 0 5 ) �於T N F - a的 
刺激下，DN組的sCTLA_4和sCD28離體增產率比NDN組和健康對照者高（全部 
P> 0 . 0 5 )；而於 I L - 1 8的刺激下’他們的離體增產率只比健康對照者高（全 
部户〉0 . 05 )。另外，DN組的SCD80離體增產率在TNF-a的刺激下卻比NDN 
組和健康對照者低（户< 0.001) ° 
在可溶性細胞點附分子的研究結果裡得知’在DN組的血裝中，可溶性 
細胞點附分子（ s I C A M ) - l � s I C A M - 3 � 可溶性血小板内皮細胞點附分子 - 1 
( sPECAM-1)和可溶性E-選擇素（ sE-se lec t in )的表達比健康對照者高（全部尸 
> 0 . 0 5 ) ，而可溶性血管細胞點附分子 - 1 ( s V C A M - 1 )和可溶性 P -選擇素 
( s P - s e l e c t i n )在N D N及D N組的表達都比健康對照者高（全部尸> 0. 0 5 ) � D N 
組的sPECAM-1和sVCAM-1表達更比NDN組高（全部户〉0. 05)�在DN組裡’sVCAM-1 




細胞裡， I L - 1 8所誘發的細胞外信號調節激酵 ( E R K )填酸化的增加率都比健康 
對照者高（全部户〉0. 0 5 ) �在N D N組的輔助性T細胞和單核細胞裡 ’ IL -18所 
誘發的p38 MAPK麟酸化的增加率都比健康對照者高（全部戶〉0.05)；同時， 
在N D N組的單核細胞裡，T N F - a所誘發的p 3 8 MAPK填酸化的增加率也比健康 
對照者高（尸> 0 . 0 5 ) �而在各組的輔助性T細胞和單核細胞裡，T N F - a和 I L - 1 8 
所誘發的 c - J u n l i基末端激酷 ( J N K )碌酸化現象則與 p 3 8 MAPK的相似。 
以上的研究結果都確定了與炎症有關分子的異常表達，以及在不同的白 
細胞裡有差別的MAPK活性，都是二型糖尿病和糖尿病賢炎的根本免疫病理機制° 
過往有研究指出在賢炎患者的血裝和尿液中的T N F - a濃度顯著增高’ 
所以我們進行了體外實驗’透過流式細胞術和酵素免疫分析法來調查TNF- a 對 
近端賢小管上皮細胞一Human Kidney (HK) -2細胞一的細胞因子、趨化因子和 
細胞表面點附分子表達的影響’以及探究細胞內MAPK調節信息轉導機制° 
研究結果顯示，TNF-a能劑量依賴性地誘發在HK-2細胞裡的趨化因子 
CCL2�細胞點附分子ICAM-1和VCAM-1表達° p38 MAPK�JNK和ERK選擇性抑制 
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Chapter 1: General Introduction 
Chapter 1 
General Introduction 
1.1 Diabetes Mellitus (DM) and Diabetic Nephropathy 
1.1.1 Prevalence, Diagnosis and Classification of DM 
Diabetes mellitus (DM) is a chronic, progressive metabolic disorder 
characterized by defects in insulin action and secretion. By 2006, 230 million people 
worldwide have been living with diabetes, which causes 3.5 million deaths annually. 
The diabetic population is predicted to be double by 2025 [International Diabetes 
Federation (IDF), 2003]. The regional estimates for DM in 2003 and 2025 are shown 
in Table 1-1. Without urgent control, the death rate will increase by 50% in the next 
10 years. Moreover, according to the Chinese National Survey in 1994 and the 
2000-2001 InterASIA Study [Gu et al, 2003], the age of onset tended to decline, 
especially in Asia. Figure 1-1 shows the prevalence of DM among Chinese adults 
aged 35 to 64 years during the past decade. 
This increasing trend of morbidity and mortality is also observed in Hong 
Kong (Figure 1-2)，in which 10 % of the population has diabetes. According to the 
Census and Statistics Department and Department of Health of Hong Kong, DM was 
the 9th commonest cause of deaths in Hong Kong, accounting for 1.6% of all deaths 
1 
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in 2005. Nevertheless, the true number of deaths is possibly higher due to late 
diagnosis and complications. 
Table 1-1. Regional estimates for DM patients aged 20 to 79 years in 2003 and 
2025. [Modified from IDF, 2003] 
2003 2025 
Region Population prevalence Population DM cases nJ^L^nce 
* (millions) ^ (%) ( • " 仙 幅 ） ^ ' ' ( o ^ l r 
AFR 295 7.1 2.4 541 15.0 2.8 
EMME 276 7.0 494 39.4 8.0 
EUR 621 48.4 7.8 646 58.6 9.1 
NA 290 23.0 7.9 374 36.2 9.7 
SACA 252 ^ 5.6 364 26.2 7.2 
SEA 705 39.3 5.6 1,081 81.6 7.5 
WP 1,384 43.0 3.1 1,751 75.8 4.3 
Total 3,823 194 5.1 5,251 333 6.3 
* AFR, Africa; EMME, Eastern Mediterranean and Middle East; EUR, Europe; NA, North America; 
SACA, South and Central America; SEA, South-East Asia; WP, Western Pacific. 
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Figure 1-1. Prevalence of DM among Chinese adults aged 35 to 64 years in 
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Figure 1-2. Age-standardized death rate of DM of different sexes in Hong 
Kong from 1981 to 2000. The age-standardized death rate was compiled based on 
the world standard population published in the 1997-99 World Health Statistics 
Annual. [Modified from the Census and Statistics Department and Department of 
Health, Hong Kong, 2005] 
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According to the World Health Organization (WHO), the 75-g oral glucose 
tolerance test (OGTT) is recommended for diagnosing diabetes. After a fasting 
glucose test，the patient is required to drink a standard amount (75 g) of glucose 
solution to challenge their system, followed by another glucose test two hours later. 
For diagnosis of DM, the fasting plasma glucose (FPG) concentration > 7 mmol/L 
should be confirmed, while a 2-hour plasma glucose level after test should be over 
11.1 mmol/L. [WHO, 1999] 
DM is suggested to be caused by insulin problem in the body. Insulin is a 
hormone enabling glucose to leave the blood and enter body tissue cells for energy 
use and controlling carbohydrate, lipid or protein metabolism. Simultaneously, 
insulin is involved in some mitogenic processes such as deoxyribonucleic acid (DNA) 
synthesis, regulation of gene transcription and altering cell growth and differentiation. 
With defective insulin production or action, glucose cannot be used or stored 
appropriately in the liver and muscles, leading to persistently high blood glucose 
concentration, i.e. hyperglycaemia. Other metabolic derangements like ketoacidosis 
may also occur. [Shoelson et al.，2007] 
According to different defects in insulin action and secretion，DM can be 
classified into 2 principal forms [IDF, 2003]: (1) type 1, characterized by failure of 
the pancreas to produce insulin; (2) type 2, resulted from the body's inability to 
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respond properly to the action of insulin produced by the pancreas, and this 
phenomenon is called "insulin resistance" which may be a post-receptor defect due 
to abnormalities in insulin signaling cascade. In the early stage of type 2 DM, insulin 
accumulation in blood causes elevated plasma insulin concentration [Shoelson et al., 
2007]. 
1.1.2 Type 2 DM and its Complication: Diabetic Nephropathy 
Since about 85 - 90 % of all DM cases are constituted by type 2，it becomes 
an increasingly important worldwide concern [IDF, 2003]. Type 2 DM generally 
occurs later in life, in those who are obese and sedentary. Other risk factors may 
include family history of diabetes, ethnicity, prolonged hypertension and 
hyperlipidaemia, etc. Undiagnosed and uncontrolled diabetes usually results in 
serious complications including peripheral- and cardio-vascular diseases, retinopathy 
and neuropathy. Up to 40% of patients, usually with chronic diabetes of over 15 
years, will develop nephropathy that is the leading cause of renal failure and 
end-stage renal disease (ESRD) [Rabkin, 2003; Ritz et al., 1999]. 
Kidney performs essential-for-life functions in the body such as filtering 
metabolic wastes and toxins along with water from blood into urine, regulating the 
volume, composition and pH of body fluids, regulating blood pressure, etc. The 
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kidney is composed of cortex and medulla, and consists of millions of nephrons. 
Each nephron acts as a basic functional unit of kidney. It filters the blood under 
pressure, then reabsorbs some necessary fluids and molecules back into blood, and 
finally secretes unneeded molecules [National Institute of Diabetes and Digestive 
and Kidney Diseases, 2005]. 
The cause of diabetic nephropathy still remains controversial. Some 
scientists suggest that glucose can bind irreversibly to proteins in the kidney and 
circulate to form advanced glycosylation end products (AGEs). These end products 
can form complex crosslinks over years of hyperglycemia and contribute to renal 
damage by stimulation of growth and fibrotic factors via receptors for AGEs 
[Caramori and Mauer，2003]. 
The earliest detectable change in the course of diabetic nephropathy is the 
thickening of basement membrane, which is the wall of glomerular capillaries in the 
nephron and normally serves as a dialyzing membrane to regulate the passage of 
water and solutes. This structural change damages the filtering ability of the 
glomeruli. At this stage, the kidney may start allowing more albumins to pass into 
urine, leading to albuminuria [Nosadini et al., 2000]. 
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1.1.3 Diagnosis and Impacts of Diabetic Nephropathy 
Creatinine is a nitrogenous waste product in the blood produced by normal 
tissue breakdown at a relatively constant rate. Almost all creatinine is excreted by the 
kidney, so plasma creatinine concentration is a good measure of kidney function. As 
kidney function deteriorates, plasma creatinine increases. Significant renal 
impairment is indicated when a baseline plasma creatinine concentration exceeds 80 
and 105 |imol/L in female and male respectively [Levey et al, 1990]. Since the 
plasma creatinine concentration eventually stabilizes as kidney impairment 
progresses, measurement of the urine albumin-.creatinine ratio (UACR) in a random 
spot sample is the preferred method to screen the stages of diabetic nephropathy in 
terms of albuminuria [American Diabetes Association (ADA), 2006]. Current 
recommendations from the ADA define the cutoff values for UACR for 
microalbuminuria and macroalbuminuria as 3.5 and 35 mg/mmol respectively, 
without regard to sex. 
According to the United Kingdom Prospective Diabetes Study in 2003 
[Adler et al., 2003], the annual transition rates through the stages of nephropathy and 
to death are shown in Figure 1-3. From any stage of nephropathy, the rate of 
deterioration to the next stage was 2 to 3% per year. With advancing nephropathy, 
the mortality rate increased. All the above data alert us that DM and diabetic 
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nephropathy have become an important public health challenge and we should 
expand our understanding of the development, progression and treatment of these 
diseases in order to avert their epidemic. 
1.1.4 Current Treatment of l ype 2 DM and Diabetic Nephropathy 
Current medication for type 2 diabetic patients is oral hypoglycaemic drugs 
like sulphonylurea, which aims at controlling DM and avoiding possible 
complications through lowering blood glucose concentration. Careful dietetic control 
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Figure 1-3. Annual transition rates through the stages of diabetic 
nephropathy and to death. [Modified from Adler et al, 2003] 
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For diabetic patients with nephropathy, angiotensin converting enzyme 
(ACE) inhibitors or angiotensin receptor blockers (ARBs) are commonly used as 
combined medication. These drugs can lower renovascular hypertension by reducing 
antgiotensin II formation that causes the muscles surrounding blood vessels to 
contract and narrows the blood vessels. Hence, the progression of nephropathy and 
renal failure is slowed [Stojiljkovic and Behnia, 2007]. 
Unfortunately, till now no remedy can be applied to cure these diseases 
completely. It has been reported that the innate immune system and cytokine-induced 
inflammatory response takes a role in DM [Jialal et al., 2002; Pickup, 2004]. Also, 
inflammation and fibrosis are involved in the pathogenesis of progressive renal 
impairment including diabetic nephropathy [Pickup, 2004]. Therefore, 
anti-inflammatory drugs are the potential therapy for these diseases, although this 
suggestion remains controversial. 
1.2 Cytokines and Chemokines 
1.2.1 Types and Properties 
Cytokines mainly consist of smaller water-soluble proteins and 
glycoproteins with a mass of 8-30 kDa. The term was firstly invented by Cohen in 
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1974, defining cytokines as a factor produced by a cell that acts in autocrine or 
paracrine manner and transduces signals among cells through specific cell surface 
receptors [Cohen and Cohen, 1996]. Cytokines are released by a diverse variety of 
cells including both haemopoietic and non-haemopoietic cells. They are particularly 
important in both innate and adaptive immune responses. Generally, cytokines are 
divided into type 1 [Interferon (INF)-Y , tumor necrosis factor (TNF)-p . ] and type 2 
[Interleukin (IL)-4, IL-10, IL-13, etc.] that promote the proliferation and functioning 
of T helper (Th) 1 and Th2 cells, respectively [O'Byrne, 2006]. Type 1 cytokines can 
maximize the killing efficacy of macrophages and the proliferation of cytotoxic T 
lymphocytes, while type 2 cytokines can stimulate B lymphocytes into proliferation, 
induce B lymphocyte antibody class switching and increase antibody production. 
Thl and Th2 responses work in a reciprocal manner and inhibit each other [Tipping 
and Kitching，2005]. 
Chemokines are small cytokines with chemotactic properties, sized between 
8 and 12 kDa. They are heparin-binding proteins comprising 4 conserved cysteine 
motifs. Chemokines are categorized into four families depending on the spacing of 
their first two cysteine residues near the amino (NH2-) terminus: CXC (a-family), 
CC (p-family), C (y-family) and CX3C (5-family), where "X" represent one amino 
acid [Homey and Zlotnik, 1999]. Mainly, chemokines can interact with their 
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corresponding receptors to regulate leukocyte trafficking, and stimulate leukocyte 
degranulation or promote angiogenesis. Chemokine receptors are G protein-coupled 
receptors with 7 transmembrane domains, usually found on the surface of leukocytes 
which are highly polarized towards Thl or Th2 phenotypes [Bonecchi et al., 1998; 
Sallusto et al., 1998]. They are divided into four families depending on the type of 
chemokines they bind: CXCR, CCR, CX3CRI and XCRl that bind CXC, CC，CX3C 
and C chemokines respectively. Evidence suggests that Thl cells preferentially 
express CXCR3 and CCR5, whereas Th2 cells preferentially express CCR3, CCR4 
and CCR8 [Qin et al., 1998]. 
The functions and sources of the major cytokines and chemokines that have 
been investigated in our project are summarized in Tables 1-2 and 1-3 respectively. 
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Table 1-2. Main functions and sources of some major cytokines. 
Name Main functions Main Sources 
XNF-a Activates macrophage and phagocytosis; Leukocytes, inflammed 
attracts neutrophils tissues 
IL-ip Induces expression of adhesion molecules; Monocytes, macrophages, 
regulates hematopiesis dendritic cells 
IL-6 Regulates B and T lymphocytes growth and T lymphocytes, macrophages 
differentiation; activates natural killer (NK) 
cells 
IL-10 Inhibits macrophage and T lymphocytes Activated Th2 cells, 
mediated immune inflammation monocytes 
IL-12 Regulates T lymphocytes growth and B lymphocytes, 
differentiation; activates NK cells macrophages 
IL-18 Induces TNF-a and Thl cytokine Activated macrophages, 
production; Regulates T lymphocytes dendritic cells 
growth and differentiation 
Adiponectin Improve insulin sensitivity; Adipocytes 
mitigate vascular damage 
12 
Chapter 1: General Introduction 
Table 1-3. Main functions and sources of some major chemokines. 
Systematica Name Main functions Main Sources 
CXCL8 Attracts migratory immune cells; Macrophages, epithelial cells 
activates neutrophils locally 
CXCL9 Attracts Thl lymphocytes INF-y activated 
macrophages 
CXCLIO Attracts Thl lymphocytes, neutrophils TNF-a/ INF-y activated 
and monocytes monocytes and neutrophils 
CCL2 Attracts monocytes, Th2 lymphocytes, Monocytes, epithelial and 
eosinophils and basophils endothelial cells 
CCL5 Attracts T lymphocytes, eosinophils TNF-a/ IL-1 a activated T 
and basophils; activates NK cells lymphocytes 
1.2.2 Cytokines and chemokines in Type 2 DM and Diabetic Nephropathy 
Previous studies have indicated the enhanced inflammation in type 2 DM is 
associated with elevated levels of the prototypic inflammatory marker C-reactive 
protein (CRP) as well as the proinflammatory cytokines TNF-a and IL-6 [Devaraj 
and Jialal, 2000; Madonna et al., 2004]. Furthermore, insulin resistance and DM are 
frequently observed in obese subjects, and differentiated adipocytes are found to 
secrete elevated level of TNF-a and IL-6 [Fasshauer and Paschke, 2003; Ohashi et 
al” 2005]. Recent researches also reported an elevation of TNF-a and IL-18 in type 2 
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diabetic patients with nephropathy [Moriwaki, et al., 2003] 
Adiponectin is an adipocytokine that is secreted exclusively from the 
adipocytes [Scherer et al., 1995]. It correlates negatively with insulin resistance, 
fasting serum triglycerides, insulin, and plasma glucose concentrations [Yamamoto et 
al” 2002]. Low plasma adiponectin concentrations have been shown in patients with 
obesity and type 2 DM [Weyer et al., 2001]. The anti-inflammatory and 
anti-atherosclerotic activity of adiponectin is supported by the reciprocal association 
between adiponectin and both CRP and IL-6 in patients with coronary atherosclerosis 
[Ouchi et al., 2003]. Adiponectin concentration has been shown to be significantly 
elevated in patients with renal diseases as well as type 1 and type 2 diabetic patients 
with impaired renal function than in healthy control subjects [Komaba et al” 2006; 
Saraheimo et al., 2005; Zoccali et a l , 2003]. 
Potential roles of chemokines CXCL8/IL-8 and CCL2/monocytes 
chemoattractant protein (MCP-1) have been proposed in the initiation and 
progression of type 2 DM and diabetic nephropathy as their plasma and urinary 
concentrations were found to be significantly higher in these diseases than in healthy 
controls [Banba et al., 2000; Tashiro et al., 2002]. These chemokines are suspected to 
mediate intrarenal inflammation in type 2 DM by recruiting macrophages, 
neutrophils and other leukocytes from blood into renal interstitium. 
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1.3 T Lymphocyte Costimulatory Molecules 
1.3.1 lypes and Properties 
The initiation of T lymphocyte activation requires a primary signal 
delivered by the antigenic peptide presented by major histocompatibility complex 
(MHC) molecules to the T cell receptor (TCR)/CD3 complex, and a nonspecific 
signal generated by the costimulatory interaction between the B7 family ligands 
[CD80 (B7-1) and CD86 (B7-2)] on antigen-presenting cells (APC) and their 
corresponding receptors [CD28, cytotoxic T lymphocyte-associated antigen-4 
(CTLA-4) and inducible costimulatory molecules] on T lymphocytes [Chambers and 
Alison, 1997; Greenfield et al, 1998] (Figure 1-4). 
Resting APC are negative for CD80 and CD86 expression, but monocytes 
and dendritic cells constitutively express CD86 [Sfikakis and Via, 1997]. Expression 
of CD80 is mainly activation-induced. CTLA-4 is a member of the immunoglobulin 
(Ig) superfamily expressed only on activated Th cells, and it is a structural 
homologue of CD28 but playing a negative regulatory role in T lymphocyte response 
[Walunas et al., 1996; Salomon and Bluestone, 2001]. Both CD28 and CTLA-4 bind 
the same ligands CD80 and CD86 expressed on APC, but CTLA-4 has a 20- to 
50-fold higher affinity than CD28 [Linsley et al, 1991]. Therefore, CD28 and 
CTLA-4 provide a critical costimulatory signal essential for the initiation and 
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progression of T lymphocyte immunity [Lenschow et al., 1996]. CD28 and CTLA-4 
actually modulate T lymphocyte-mediated immune responses in a reciprocal manner. 
The soluble forms of these costimulatory molecules usually come from shedding of 
the membrane forms or messenger ribonucleic acid (mRNA) alternative splicing. 
[Jeannin et al., 2000; Magistrelli et al, 1999; Magistrelli et al., 1999] 
1.3.2 T Lymphocyte Costimulatory Molecules in Type 2 DM and Diabetic 
Nephropathy 
The investigation of plasma soluble costimulatory molecules is a raising 
topic in the field of immunology. Till now, there are no findings about the expression 
of soluble costimulatory molecules in type 2 DM and diabetic nephropathy. Our 
group has previously reported an aberrant production of soluble (s) CTLA-4, sCD28, 
sCD80 and sCD86 in patients with systemic lupus erythematosus (SLE) and asthma 
[Ip et al” 2005; Ip et al” 2006; Wong et al., 2005; Wong et al” 2005], suggesting that 
dysregulation of T lymphocyte costimulation might contribute to the 
immunopathogenesis in autoimmune disease and inflammation. Therefore, in our 
present study, we have attempted to evaluate the immunopathological roles of these 
soluble costimulatory molecules in type 2 DM and diabetic nephropathy and search 
for new potential surrogate markers of these diseases. 
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Figure 1-4. A schematic diagram illustrating the interactions of costimulatory 
molecules. Upon encountering APC, the interaction of costimulatory molecules 
elicits different response of T lymphocytes. 
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1.4 Adhesion Molecules 
1.4.1 lypes and Properties 
Adhesion molecules are specific cell surface proteins involved in mediating 
adhesion of cells to each other and of cells to extracellular matrix structures. They 
are classified into several discrete groups that include integrins, cadherins, members 
of the Ig superfamily, and selectins [Radi et al., 2001]. Members of Ig superfamily 
and selectins are the main focus of this part. 
In the immune system, Ig superfamily members play a critical role in 
cellular adhesion. Key members include the intercellular adhesion molecules 
(ICAM)，of which there are now five members, vascular cell adhesion molecule-1 
(VCAM-1), and mucosal vascular addressin cell adhesion molecule-1 (MAdCAM-1) 
[Petruzzelli et al., 1999]. These proteins serve as ligands of integrins and their 
adhesive interactions depend on the endothelial cell and the individual leukocyte 
examined. In contrast, platelet endothelial cell adhesion molecule-1 (PECAM-1), 
another member of Ig superfamily, can also exhibit homotypic molecular interactions 
[Rojas and Ahmed, 1999]. 
Selectins form the newest family of adhesion molecules. Their major 
function is recruiting leukocytes from circulation. It is a small family comprised of 
L-，E-, and P-selectins and is associated with rolling of leukocytes along the 
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endothelial cell wall [Lay, 2003]. 
In our present project, we have attempted to investigate the plasma 
concentration of sICAM-1, sICAM-3, sPECAM-1, sVCAM-1, sE- and sP-selectins 
in type 2 diabetic patients and those with nephropathy and their possible association 
with the pathogenesis of these diseases. Their structures and major functions are 
illustrated in Figure 1-5. 
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Figure 1-5. A schematic diagram illustrating the structures, corresponding 
ligands and main functions of different adhesion molecules that were 
investigated in the present project. 
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1.4.2 Adhesion Molecules in Type 2 DM and Diabetic Nephropathy 
ICAM-1, VCAM-1 and E-selectin are the most commonly studied adhesion 
molecules in type 2 DM and diabetic nephropathy. Contradicting data about the 
expression of sICAM-1 in these diseases have been reported. Steiner et al. and 
Gibson et al. reported that plasma sICAM-1 was not associated with type 2 DM and 
nephropathy [Gibson et al., 1997; Steiner et al., 1994], incompatible with the data 
reported by Kado et al. and Guler et al. that plasma sICAM-1 increased in diabetic 
patients and those with nephropathy [Kado and Nagata, 1999; Guler et al., 2002]. It 
was suggested that upregulated ICAM-1 might promote recruitment of mononuclear 
cells in diabetic nephropathy [Guler et al., 2002]. Besides, sVCAM-1 and sE-selectin 
have also been found to be upregulated in type 2 DM and diabetic nephropathy 
[Matsumoto et al” 2002]. Their high expression might reflect endothelial activation 
and damage in these diseases. Unfortunately, the associations of sICAM-3, 
sPECAM-1 and sP-selectins with type 2 DM and diabetic nephropathy have not been 
explored yet, although some literatures reported a significantly higher expression of 
E- and P-selectins in renal tissue of patients with diabetic nephropathy than normal 
[Hirata et al.，1998]. 
20 
Chapter 1: General Introduction 
1.5 Intracellular Signaling Pathways 
1.5.1 Types and Properties 
Among all signal transduction pathways that have been identified nowadays, 
mitogen-activated protein kinase (MAPK) pathways are the most well known and 
established. They consist of 3 major pathways: p38 MAPK, c-Jun NH2-terminal 
kinase (INK) and extracellular-regulated protein kinase (ERK) cascades, of which 
the mechanism of activation is depicted in Figure 1-6. 
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Figure 1-6. A schematic diagram illustrating the 3 major cascades of MAPK 
intracellular signal pathways: p38 MAPK, JNK and ERK cascades. 
Phosphorylation of downstream kinases and transcription factors leads to expression 
of inflammatory molecules and different cellular physiological responses. 
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The p38 MAPK pathway mainly regulates cellular degranulation, 
chemotaxis and expression of adhesion molecules during inflammation. Besides, it 
also regulates cell cycle progression, differentiation and apoptosis [Aouadi et al., 
2006]. p38 MAPK is a stress-activated protein kinase and can be activated by 
osmotic stress, ultra-violet radiation, ionizing radiation, bacterial cell wall product 
lipopolysaccharide (LPS) and various proinflammatory cytokines such as TNF-a and 
IL-ip [Kyriakis and Avruch, 2001]. Upon activation, p38 MAPK is subjected to 
phosphorylation which in turn activates a variety of downstream transcription factor. 
JNK is a protein kinase cascade responsible for transducing cellular stress 
signals and can be potently activated by irradiation, inflammatory cytokines and 
other environmental stresses like hyperosmclarity [Derijard et al., 1994]. JNK 
enhances the transcriptional activity of AP-1 by phosphorylation [Hibi et al., 1993]. 
Binding sites for AP-1 exist in the promoter regions of several cytokine genes including 
those encoding CXCL8 and CCL5/regulated upon activation normal T-cell expressed 
and secreted (RANTES) [Mukaida et al, 1989; Nelson et al., 1993]. 
The ERK pathway mainly takes part in regulating cell proliferation, 
transformation and differentiation after being activated by growth factor like IL-5 [de 
Groot et al., 1998; Eblen et al” 2002]. ERK activation can induce CXCL8 production 
from neutrophils during inflammation [Jo et al., 2004]. Moreover, its inhibition can 
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repress lung inflammation via suppressing the Th2 cytokines production [Chialda et 
al , 2005]. Upon activation, ERKs are phosphorylated, dimerized and translocated 
into nucleus, where they in turn phosphorylate downstream transcription factors for 
eliciting biological responses [Eblen et al., 2002]. 
1.5.2 Intracellular Signaling Pathways in Type 2 DM and Diabetic 
Nephropathy 
ERK and p38 MAPK have been found to play important roles in 
inflammation by inducing the production of inflammatory cytokine IL-6 and 
chemokine CXCL8，CCL2, CCL5, CXCL9/monokine induced by IFN-y (MIG) and 
CXCLIO/IFN-丫-inducible protein-10 (IP-10) [Wong et al., 2005; Wong et al., 2005]. 
It has been shown that diabetic nephropathy is mediated, at least in part, by 
intracellular cell signaling mechanism through the p38 MAPK pathway of 
macrophages in kidney tissue [Adhikary et al., 2004], since increased phosphorylated 
p38+ macrophages have been found in the kidney of diabetic patients. Basal p38 
MAPK phosphorylation is also increased in skeletal muscle of type 2 diabetic 
patients [Koistinen et al., 2003]. However, the detailed dysregulation of various 
intracellular signal transduction molecules of lymphocytes in type 2 DM and diabetic 
nephropathy is not well defined. 
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1.6 Objectives of Our Study 
To summarize the above findings about the pathogenesis of diabetic 
nephropathy, inflammation has been postulated to be a potential pathogenic 
mechanism, exemplified by increased plasma and urinary levels of cytokines and 
chemokines, which are secreted by endothelial, mesangial, glomerular and tubular 
epithelial cells, as well as infiltrating leukocytes, via the activation of various 
intracellular signaling pathways in the inflamed renal tissues. 
However, these findings have inspired us a number of questions, which in 
turn became the objectives of our project: 
(1) Were there any other inflammatory molecules involved in diabetic patients 
with or without nephropathy? Were they different in the Chinese 
population? 
(2) If intra-renal inflammation really occurred, what was happening at the time 
of stimulation in the inflammatory sites? Was there any abnormal immune 
response of immune cells upon those stimulations? 
(3) Were there any activations of other intracellular signaling pathways in other 
immune cells that are associated with diabetic nephropathy? 
Hence, our project was divided into 2 parts: clinical and in vitro studies. In 
the clinical study, we recruited healthy people and diabetic patients with various 
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degrees of nephropathy to have plasma and cell analyses. In the in vitro study，we 
treated human proximal tubular epithelial cells (PTEC) with TNF-a so as to mimic 
the local inflammatory effect in the kidney of patients with diabetic nephropathy or 
other chronic kidney diseases, followed by investigating the expression profile of 
inflammatory molecules and the underlying signaling mechanism. 
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Chapter 2 
Materials and Methods 
2.1. Materials 
2.1.1. Patients, Control Subjects and Blood Samples 
Ninety-four Chinese adult patients with type 2 DM were recruited from the 
Diabetes Mellitus and Endocrine Centre of the Prince of Wales Hospital, Hong Kong. 
DM was diagnosed using oral glucose tolerance test according to the WHO criteria: 
FPG > 7.0 mmol/L or a 2-hour glucose concentration > 11.1 mmol/L [WHO, 1999]. 
All subjects were non-smokers and free from infection for four weeks preceding the 
study. The DM patients were further divided into two groups (Table 2-1): (1) 
patients with normoalbuminuria and plasma creatinine < 80 (female)/ 105 (male) 
|j,mol/L [patients without diabetic nephropathy (NDN), n = 28], and (2) patients with 
albuminuria [fasting UACR > 3.5 mg/mmol in 2 urine samples] and plasma 
creatinine > 80 (female) / > 105 (male) fimol/L [patients with diabetic nephropathy 
(DN), n = 66]. Body weight, body height, waist and hip circumferences were 
measured for the determination of waist: hip ratio (WHR) and body mass index 
(BMI). Twenty sex- and age-matched healthy Chinese volunteers were recruited as 
control subjects (CTL). Twelve milliliters of venous peripheral 
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ethylenediaminetetraacetic acid (EDTA) blood was collected from each participant. 
Aliquots of whole blood were processed immediately for ex vivo study and 
fractionation of peripheral blood mononuclear cells (PBMC). Plasma were 
separated from blood cells by centrifugation (2000 g for 10 minutes) at 4°C and 
stored in 300 aliquots at -70°C until analysis. The above protocol was approved by 
the clinical research ethics committee of the Chinese University of Hong Kong-New 
Territories East Cluster Hospitals, and informed consent was obtained from all 
participants according to the Declaration of Helsinki. 
Table 2-1. Groups of participants recruited in our clinical study. 
I  Groups CTL NDN DN 
Number of Participants (n) 20 28 66 
Type 2 DM X V V 
Female < 80 80 < Female < 150 
Plasma Creatinine (jxmol/L) 
Male < 105 105 < Male < 150 
UACR (mg/mmol) j ^ ^ 
CTL, controls; NDN, type 2 diabetic patients without nephropathy; DN, type 2 diabetic patients with 
nephropathy. 
2.1.2. Cell Line 
All in vitro experiments were performed using Human Kidney (HK)-2 cells 
purchased from American Type Culture Collection, MA, USA. The cells were 
human proximal tubular epithelial cells from normal adult kidney, immortalized by 
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transduction with human papilloma virus (HPV) 16 E6/E7 genes [Ryan et al., 1994]. 
2.1.3. Cell Culture Media, Buffers and Other Reagents 
(1) RPMI 1640 Medium 
RPMI 1640 medium, supplemented with 25 mM 
N-2-hydroxy-ethyl-piperazine-N'-2-ethane sulfonic acid (HEPES) buffer and 
L-glutamine, was used for whole blood culture and purchased from Gibco Invitrogen 
Corp, CA, USA. 
(2) Dulbecco's MEM:Ham's Nutrient Mixture F-12 (DMEM:F-12) Medium 
DMEM:F-12 medium (1:1 mix), supplemented with 15 mM HEPES buffer, 
L-glutamine and pyridoxine HCl and free of detectable LPS [<0.1 EU (endotoxin 
units)/mL], was used to culture HK-2 cells and purchased from Gibco. 
(3) Serum Supplement to Culture Medium 
Fetal calf serum (FCS) was purchased from Hyclone Co, MA, USA. It had 
been tested with low endotoxin (<10 EU/mL) and hemoglobin (<10 mg/mL) level. 
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(4) Phosphate-Buffered Saline (PBS) solution 
Dulbecco's PBS (DPBS) powder packs without calcium and magnesium 
were purchased from Gibco Invitrogen Corp. PBS solution (1 L) was prepared by 
dissolving one powder pack in 1 L deionized water, which was then sterilized by 
autoclave before use. 
(5) Trypsin-EDTA (0.05 %) 
Trypsin-EDTA (0.05 %, IX) solution was purchased from Gibco and stored 
at -20 °C until use. It was porcine parvovirus and mycoplasma tested, containing 0.5 
g/L of trypsin (1:250) and 0.2 g/L of EDTA.4Na in Hanks' Balanced Salt Solution 
without CaCl2, MgCb • 6H2O，and MgSO* • 7H2O. 
(6) Endotoxin-free solution 
All solutions were prepared using pyrogen-free water and sterile 
polypropylene plasticware. No solution contained detectable LPS, as determined by 
the Limulus amoebocyte lysate assay (sensitivity limit 12 pg/ml; Cambrex Bio 
Science Walkersville Inc, MD, USA) 
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(7) Ficoll-Paque™ PLUS solution 
This product was purchased from GE Healthcare Life Sicence, CA, USA, 
and used for isolation of PBMC from human peripheral blood. 
2.1.4. Recombinant Human Cytokines, Inhibitors and Other Stimulators 
(1) Recombinant Human TNF-a 
Recombinant human TNF-a was purchased from PeproTech Inc, NJ, USA. 
It was a lyophilized recombinant protein derived from Escherichia coli (E. coli) with 
specific activity of > 2 x 10^  units/mg. It was reconstituted to 20 jig/mL in sterilized 
PBS solution and kept as 50 |jL aliquots at -80 
(2) Recombinant Human IL-18 
IL-18 was purchased from Medical & Biological Laboratories Co Ltd, 
Nagoya, Japan. It was a lyophilized recombinant protein derived from E. coli. It was 
reconstituted to 10 |ag/mL in sterile PBS solution and kept as 20 )j.l aliquots at -80 
(3) Signal transduction pathway inhibitors 
They were purchased from Calbiochem, CA, USA. SB 203580, SP600125 
30 
Chapter 2: Materials and Methods 
and PD98035 were potent selective p38 MAPK inhibitor, JNK inhibitor and ERK 
inhibitor respectively. SB203580 was a pale yellow, water-soluble solid and 
reconstituted to 10 mM in autoclaved distilled water. SP600125, a lyophilized white 
solid, and PD98058, a pale yellow solid, were reconstituted to 100 mM and 20 mM 
in dimethyl sulfoxide (DMSO) respectively. In all studies, the concentration of 
DMSO was 0.1 %. All aliquots of inhibitors were stored at -80 °C and protected 
from light. 
(4) LPS 
This product was phenol extract from E. coli and purchased from Sigma 
Chemical Co, MO, USA. It contained endotoxin levels of not less than 500,000 
EU/mg. LPS was reconstituted to 1 mg/mL in sterile PBS solution and stored at -20 
until use. 
2.1.5. Reagents and Buffers for Flow Cytometric Analysis 
(1) Human Serum 
Human serum for blocking procedure in immunofluorescent staining was 
obtained from venous blood of Chinese healthy volunteers and stored at -20 
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(2) FACSFlow sheath fluid 
It was purchased from BD Bioscience Corp, NJ, USA and was a balanced 
electrolyte solution containing sodium chloride, potassium chloride, disodium EDTA, 
sodium fluoride and anti-microbial agent. 
(3) FACS medium 
It was prepared by dissolving 0.05 g of sodium azide (NaNs) in 100 mL of 
PBS supplemented with 2 % fetal bovine serum (FBS) and stored at 4 
(4) CaliBRITE™ Beads 
CaliBRITE丁M beads, purchased from BD Biosciences, were used to 
calibrate the cytometer including adjusting instrument settings, setting fluorescence 
compensation and checking instrument sensitivity. 
(5) Paraformaldehyde (1%) 
Paraformaldehyde powder (10 g), purchased from Sigma, was dissolved in 
1 L of IX PBS for cell fixation. 
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2.1.5.1. Cytometric Bead Array (CBA) of Cytokines and Chemokines 
Human Chemokine CBA Kit I for measurement of CXCL8, CXCL9， 
CXCLIO, CCL2, CCL5, and Human Inflammation CBA Kit for measurement of, 
TNF-a, IL-ip，IL-6, IL-10, IL-12p70 and CXCL8, were purchased from BD 
Biosciences. The kits contained cytometer setup beads, phycoerythrin (PE) positive 
control detector, fluorescein isothiocyanate (FITC) positive control detector for 
compensation settings. It also contained five (for chemokines kit) or 6 (for 
inflammation kits) populations of capture beads with corresponding monoclonal 
antibodies, PE-conjugated detection reagents, standards and wash buffer for 
cytokines or chemokines detection in plasma or supernatants. 
2.1.5.2. Multiplex Fluorescent Bead Immunoassay (FBI) of Soluble Adhesion 
Molecules 
FBI - FlowCytomix (human adhesion molecules 6plex) kit was purchased 
from Bender MedSystems, Vienna, Austria for measurement of sICAM-1, sICAM-3, 
sPECAM-1, sVCAM-1, sE- and sP-selectins. The kits contained 6 populations of 
capture beads with corresponding monoclonal antibodies, PE-conjugated secondary 
antibodies, standards and wash buffer for detection of soluble adhesion molecules in 
plasma or supernatants. 
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2.1.5.3. Phosphorylation State Analysis of Signaling Molecules 
BD™ Phosflow phosphorylation state analysis was applied. All reagents 
and buffers were purchased from BD Biosciences and listed below: 
(1) BD Cytofix buffer 
It was comprised of DPBS at pH 7.4 with 4 % paraformaldehyde. It was 
used to fix unstained cells for subsequent immunofluorescent staining of intracellular 
kinases and stored at 4 °C. 
(2) Perm Buffer III 
It was a buffered solution containing 90 % methanol and other proprietary 
ingredients and could be stored at room temperature. It was used for permeabilization 
following fixation of cells. 
(3) Stain Buffer 
It was DPBS with 2 % heat-inactivated FBS and 0.09 % sodium azide at pH 
7.4 and stored at 4 It was useful for the dilution and application of fluorescent 
reagents as well as for the suspension, washing and storage of cells destined for flow 
cytometric analysis. 
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(4) Monoclonal Antibodies 
The monoclonal antibodies applied in this analysis are listed in Table 2-2. 
All of them were stored at 4 °C. 
Table 2-2. List of monoclonal antibodies used in phosphorylated state analysis 
using flow cytometry. 
Monoclonal Fluorescence Stock Amount added Supplier 
Antibodies Conjugation Cone. per 10® cells 
Mouse IgGi Purified 50 |_ig/ml 8 [i\ BD Biosciences 
anti-human 
phospho-p38 MAPK 
Mouse IgGi Purified 50 |ag/ml 8 BD Biosciences 
anti-human 
phospho-JNK 
Mouse IgGi Purified 50 |ag/ml 8 |il BD Biosciences 
anti-human 
phospho-ERKl/2 
Mouse IgG] Isotype Purified 50 |ig/ml 8 |il BD Biosciences 
Goat anti-mouse IgGi FITC 3 M-g/ml 80 Zymed Laboratories 
35 
Chapter 2: Materials and Methods 
2.1.5.4. Immunofluorescent Staining of Cell Surface Molecules 
The anti-human monoclonal antibodies against cell surface molecules used 
in this project are summarized in Table 2-3. All of them were stored at 4 
Table 2-3. List of monoclonal antibodies used in immunofluorescent staining of 
cell surface molecules. 
Monoclonal Fluorescence Stock Cone. Amount added Supplier 
Antibodiges Conjugation per 10^ cells 
Mouse IgG, FITC 50 ^ig/ml 4 |il R & D Systems 
anti-human ICAM-1 
Mouse IgGi PE 50 p-g/ml 4 |al BD Biosciences 
anti-human VCAM-1 
Mouse IgGi PE 50 tests/ml 4 BD Biosciences 
anti-human CD4 
Mouse IgGi Isotype FITC 50 |ig/ml 8 i^l BD Biosciences 
Mouse IgGi Isotype PE 50 |ig/ml 8 |_il BD Biosciences 
Mouse IgG2a Isotype FITC 50 |ag/ml 8 |il BD Biosciences 
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2.1.6. Reagents and Buffers for Protein Array Analysis 
RayBio® Human Cytokine Antibody Array V Kit was purchased from 
RayBiotech Inc，GA, USA. The kit consisted of RayBio® human cytokine Antibody 
array membranes, biotin-conjugated anti-cytokines, horseradish peroxidase 
(HRP)-conjugated streptavidin, 2X blocking buffer, wash buffers I and II, detection 
buffer C and detection buffer D. 
2.1.7. Reagents and Buffers for 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyIy-
tetrazolium bromide (MTT) Assay 
MTT was purchased from Simga-Aldrich Inc, MO, USA. MTT was 
dissolved in PBS to 5mg/mL and stored at -4°C. 
2.1.8. Reagents for Human Enzyme-Linked Immunosorbent Assay (ELISA) 
Table 2-4 shows the sources of the human ELISA kits used in this project, 
their corresponding sensitivities and % CV of intra- and inter-assay precisions. 
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Table 2-4. List of human ELISA kits used in this project. 
ELISA Kits Sensitivity % CV of % CV of Supplier 
intra-assay inter-assay 
precision precision 
sCTLA-4 0.2 ng/mL 4.8 10.4 Bender MedSystems 
sCD28 0.18 ng/mL 5.9 7.2 Bender MedSystems 
sCD80 0.1 ng/mL 7.2 9.2 Bender MedSystems 
sCD86 0.14 ng/mL 7.2 7.8 Bender MedSystems 
Adiponectin 0.25 ng/mL 3.5 6.5 R & D Systems 
IL-18 12.5 pg/mL 7.3 7.5 Biosource 
MCP-1 1.0 pg/mL 10 8.5 BD OptEIA 
2.2. Methods 
2.2.1. Whole Blood Culture Experiments 
The method of Viallard et al. (1999) was adopted for the culture of human 
EDTA blood. Whole blood (500 )j.L) was cultured with equal volume of culture 
medium RPMI 1640 and specific activators in 24-well plates (Nalge Nunc 
International, IL, USA). Activators used for ex vivo studies included human 
recombinant TNF-a (150 ng/mL) and IL-18 (150 ng/mL). The cultures were 
incubated at 37 °C for 24 hours in a 95 % humidified incubator supplied with 5 % of 
carbon dioxide (CO2). After incubation, the cell-free supernatants were collected by 
centrifugation at 4 twice, at 2000 g for 10 minutes followed by 16000 g for 
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another 10 minutes, and finally stored at -80 for future assays. 
2.2.2. Collection of Serum and Plasma, and Purification of PBMC from 
EDTA-Blood 
Cell-free serum and plasma were collected by centrifuging 6 mL of clotted 
blood and 9 mL of EDTA-blood respectively at 4 °C twice, at 2000 g for 10 minutes 
followed by 16000 g for another 10 minutes. They were stored at -80 for future 
assays. 
Remaining buffy coat of EDTA-blood (3 mL) was diluted with equal 
volume of PBS and slowly layered onto the top of 8 mL of Ficoll-Paque PLUS 
density gradient column. The column was centrifuged at 1800 rpm for 25 minutes at 
18 without acceleration and deceleration. After centrifugation, 4 layers of fluids 
appeared in the column. The thin white interface between the top and third layers 
contained the viable PBMC including lymphocytes and monocytes. The cells were 
washed twice and resuspended with PBS for subsequent phosphorylation state 
analysis of signaling molecules. 
2.2.3. HK-2 Cell Cultures 
HK-2 cells were grown in DMEM:F12, with 15 mM HEPES, L-glutamine 
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and pyridoxine HCl，supplemented with 10 % FCS (Gibco). The cells were incubated 
at 37 °C in a 95 % humidified incubator supplied with 5 % of CO2 and passaged 
every 2-3 days at about 80% of confluence. 
2.2.4. HK-2 Cell Treatments 
HK-2 cells were seeded and serum-deprived in 96-well, 24-well or 6-well 
culture plates for 16 hours until 70-80 % confluence before any experimental 
manipulation. All experiments were performed in serum-free conditions so that the 
cell remained viable in a non-proliferating state. Seeded cells were treated with or 
without stimulator, TNF-a (20 ng/mL), for various time periods as indicated in 
different experiments. For inhibition assays, the cells were firstly treated with 
inhibitors for 1 hour prior to stimulations. After all treatments, medium were 
collected and centrifuged. The cell-free supernatants were then stored at -80 for 
future assays. 
The cells remaining on the plates were rinsed with PBS and harvested with 
short exposure to 0.05 % (w/v) trypsin-EDTA (Gibco) and gentle shaking. They were 
then washed and resuspended with PBS, and ready for subsequent 
immunofluorescent staining of cell surface adhesion molecules and phosphorylation 
state analysis of signaling molecules. 
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2.2.5. Flow Cytometric Analysis 
2.2.5.1. CBA of Cytokines and Chemokines 
Inflammatory cytokines including TNF-a, IL-1(3, IL-6, IL-10 and IL-12p70 
and chemokines including CXCL8，CXCL9, CXCLIO, CCL2 and CCL5 were 
measured with Human Inflammation CBA Kit and Human Chemokine CBA Kit I 
(BD Pharmingen) respectively by flow Cytometry (FACSCalibur, BD Biosciences). 
The inflammatory cytokine and chemokine CBA kits contained 6-bead and 5-bead 
populations respectively with distinct fluorescence intensities. These beads were 
coated with capture antibodies specific for different cytokines and chemokines. The 
bead populations could be resolved in the FL4 channel of flow cytometer. First, 50 
|iL of plasma or culture supernatants were incubated with 50 )iL of different capture 
beads mixtures and 50 |jL of PE-conjugated detection antibodies. The mixture was 
incubated at room temperature for 3 hours and allowed to form a sandwich complex. 
After all, the capture beads were washed and resuspended for sample data acquisition 
with Cell Quest (FACSCalibur) and analyzed with BD CBA analysis software. 
2.2.5.2. Multiplex FBI of Soluble A dhesion Molecules 
Soluble adhesion molecules including sICAM-1, sICAM-3，sPECAM-1, 
sVCAM-1, sE- and sP-selectins were measured with FlowCytomix (human Adhesion 
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6plex) kit (Bender MedSystems) using FACSCalibur. The kit contained 6-bead 
population with distinct fluorescence intensities. These beads were coated with 
capture antibodies specific for different soluble adhesion molecules. The bead 
populations could be resolved in the FL4 channel of flow cytometer. First, 25 (iL of 
plasma or culture supernatants were incubated with 25 \iL of different capture beads 
mixtures and 50 fjL of PE-conjugated detection antibodies. The mixture was 
incubated at room temperature for 2 hours and allowed to form a sandwich complex. 
After all, the capture beads were washed and resuspended for sample data acquisition 
with Cell Quest (FACSCalibur) and analyzed with BMS flowCytomix Pro software. 
22.5.•？. Phosphorylation State Analysis of Intracellular Signaling Molecules 
BD™ Phosflow activation state analysis (BD Biosciences) was used. 
Resting, TNF-a- or IL-18-stimulated (20 ng/mL) PBMC or HK-2 cells (1 x 10^ cells 
/ml) were fixed with an equal volume of pre-warmed BD Cytofix Buffer. The 
fixation was carried out immediately after 15-minute stimulations during which the 
cells were incubated at 37 °C for 10 minutes. They were then collected by 
centrifugation at 300 g for 5-10 minutes. BD Phosflow Perm Buffer III (1 mL) was 
added to permeabilize the cells for 30 minutes on ice. Cells were washed twice and 
resuspended with BD Pharmingen Stain Buffer. They were then incubated with 
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mouse anti-human phospho-p38, phospho-pJNK and phospho-ERK monoclonal 
antibodies or mouse IgGi Isotype at 4 °C for 45 minutes in dark, followed by 
incubation with FITC-conjugated goat anti-mouse IgG secondary antibody (1:200) at 
4 for 1 hour in dark. For PBMC, after the incubation with secondary antibody, 
they were further co-stained with PE-conjugated mouse anti-human CD4 monoclonal 
antibodies at 4 for 30 minutes in dark so as to distinguish the CD4+ 丁 lymphocyte 
population among them. After a final wash, cells were resuspended in 1 % 
paraformaldehyde in PBS. Quantitative analysis of the expressions of intracellular, 
phosphorylated signaling molecules in terms of mean fluorescence intensity (MFI) 
was performed with Cell Quest (FACSCalibur). 
2.2.5.4. Immunofluorescent Staining of Cell Surface Molecules 
Treated HK-2 cells (6 x 10^  cells) were harvested and resuspended with 
cold IX PBS. After being blocked with 2 % human pooled serum at room 
temperature for 15 minutes and washed with PBS, cells were incubated with the 
aforementioned monoclonal antibodies at 4 °C in dark for 45 minutes. After a final 
washing, cells were fixed with 1 % paraformaldehyde in PBS. Expressions of cell 
surface parameters were then quantitatively analyzed with Cell Quest (FACSCalibur) 
in terms of MFI. 
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2.2.6. Protein Array Analysis 
RayBio® Human Cytokine Antibody Array V Kit (RayBiotech Inc, GA, 
USA) was used to investigate the expression profiles of 79 different human cytokines 
in plasma or supernatant samples. The whole experiment was carried out at room 
temperature. Array membrane was first blocked with blocking buffer for 30 minutes 
and then incubated with the sample for 1.5 hours. It was washed and incubated with 
biotin-conjugated antibodies for further 1.5 hours. After washing, HRP-conjugated 
streptavidin was used to incubate the membrane for 2 hours. The membrane was 
washed again, incubated with 1:1 mixed detection buffers C and D and finally 
exposed to x-ray film. The resulting band intensities were analyzed with Bio-Rad 
Quantity One™ software (Bio-Rad Laboratories, Hercules, USA). 
2.2.7. MTT Assay 
HK-2 cells (4 x lO'^  cells/ 0.2 mL) were inoculated into a 96-well plate. 
Drugs or inhibitors with various concentrations were added to the cells. After 
24-hour incubation, the cells were further treated with 40 jiL of MTT solution (5mg/ 
mL in PBS; Sigma) and incubated for 4 hours. MTT was absorbed by viable cells 
and then reduced by the mitochondrial dehydrogenase into dark blue water-insoluble 
formazan. Cells were collected by centrifugation at 1500 rpm for 5 minutes and lysed 
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with 200 \iL of DMSO. Absorbance of the final products was measured at 550 nm 
with VICTOR^ Multilabel Counter Model 1420-032 (PerkinElmer Life And 
Analytical Sciences Inc, MA, USA). The readings were directly proportional to cell 
viability and proliferation of the cells. 
2.2.8. ELISA 
Concentrations of cytokines adiponectin and IL-18, chemokine CCL2 and 
soluble costimulatory molecules sCTLA-4, sCD28, sCD80 and sCD86 in the plasma 
or supematants collected were detected with the corresponding ELISA kits (Bender 
Med Systems; R & D Systems; Biosource; BD OptEIA; Table 2-5). Samples and 
standards were added to the microwells coated with monoclonal antibody, followed 
by the incubation with biotin-conjugated antibody and HRP-streptavidin. Unbound 
biotin-conjugated antibody and HRP-streptavidin were removed during a wash step. 
Substrate solution reactive with HRP was then added to the wells. The reaction was 
terminated by addition of acid, and the absorbances of the final enzymatic products 
were measured at 450 nm with VICTOR� Multilabel Counter Model 1420-032 
(PerkinElmer). The detection limits of the assays were 0.2，0.18, 0.1, 0.14, 0.25 
ng/mL, 12.5 and 1.0 pg/mL，respectively. Intra-assay coefficients of variation were 
all < 1 0 % . 
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2.2.9. Statistical Analysis 
Data are presented in column graphs or x-y plots as mean with standard 
error of measurement (SEM), or in box-and-whiskers plots as median with 
interquartile range (IQR) (25 % and 75 % percentiles), minimum and maximum 
values. When two data groups were compared, two-tailed Mann-Whitney rank sum 
test or Student's t test was applied respectively for non-parametric or normally 
distributed numerical variables. Comparisons among three or more data groups were 
assessed with non-parametric analysis of variance (ANOVA), Kruskal-Wallis test. 
After ANOVA had revealed significant differences among groups, post hoc Dunn's 
multiple comparison test was performed for pairwise comparisons. Correlations 
between variables were tested with Spearman's rank correlation coefficient. P values 
less than 0.05 were considered as statistically significant. All statistical analyses were 
achieved with statistical software, GraphPad Prism for Windows (version 3.00, 
GraphPad Software Inc, CA, USA) 
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Chapter 3 
Clinical Study on the Expressions of Cytokines, 
Chemokines，Costimulatory Molecules, 
Adhesion Molecules and Phosphorylated 
Signaling Molecules in Patients with Diabetic 
Nephropathy 
3.1. Introduction 
According to the objectives of our project specified in Chapter 1，the 
clinical study was divided into 3 aspects in order to expand our understanding step 
by step. Firstly, plasma of different patient cohorts and healthy subjects were 
obtained for screening and assaying the expression profile of soluble inflammatory 
molecules. Secondly, whole blood assays were carried out to examine the ex vivo 
release of inflammatory molecules from leukocytes upon activations by TNF-a and 
IL-18. The purpose of these assays was to preserve the molecular environment for 
leukocyte activation, which could hence more accurately reflect the 
immunocompetence or secretory capacity of the leukocytes at the time of stimulation 
in the local inflammatory sites. TNF-a and IL-18 were previously found to be 
elevated in the plasma of type 2 DM patients with nephropathy [Moriwaki et al., 
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2003]. They are regarded as upstream cytokines which can induce the release of 
many cytokines or chemokines from leukocytes, and they are suspected to be 
released locally in inflamed kidney tissue [Moriwaki et al., 2003; Navarro and 
Mora-Fernandez, 2006]. Hence, we postulated that the leukocytes of diabetic patients 
with nephropathy might behave abnormally around the inflammatory sites upon 
activations, when compared with those healthy people. 
Thirdly, PBMC, mainly consisting of lymphocytes and monocytes, were 
collected for intracellular signaling analysis. The expressions of phosphorylated p38 
MAPK, ERK and JNK in the resting state or activated stated of Th cells and 
monocytes upon TNF-a or IL-18 stimulation were investigated. Based on our 
previous studies of intracellular signal transduction mechanisms in inflammation, our 
hypothesis was that intracellular signaling molecules ERK, p38 MAPK and JNK, 
together with proinflammatory cytokines, chemokines, soluble costimulatory 
molecules and soluble adhesion molecules form a network in orchestrating 
inflammation in diabetic nephropathy. 
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3.2. Results 
3.2.1. Demographic Data of Participants 
Sixty-six DM patients with nephropathy (DN), 28 DM patients without 
nephropathy (NDN) and 20 sex- and age-matched control subjects were studied. 
Their age, sex, FPG，plasma creatinine concentrations, UACR, BMI and WHR are 
summarized in Table 3-1. The plasma creatinine and UACR were significantly 
higher in DN patients than NDN patients, thereby indicating the nephropathy in DN 
patients. 
Table 3-1. Demographic data of the type 2 diabetic patients and control subjects. 
CTL NDN DN 
Number 20 28 66 
Sex (Male/Female) 12/8 18/10 32/34 
Age (years) 46.5 (41.0-51.0) 56.5 (53.0-59.0) 57.0 (54.5-60.5) 
FPG (mmol/L) 5.1 (4.9-5.4) 7.5 (5.8-8.4)^ 7.7 (6.2-9.0)'' 
‘ Plasma Creatinine Oimol/L) 81.0 (71.5-88.0) 88.0(77.5-100.0) 114.5 (96.0-129.0广’。 
UACR (mg/mmol) <3.50 2.35 (0.95-3.50) 34.0 (3.7-107.9)� 
BMI 23.0(21.2-24.5) 25.4 (23.0-29.1)" 25.8 (24.3-28.l)b 
WHR 0.84 (0.81-0.86) 0.94 (0.88-0.97)'' 0.93 (0.89-0.98)^ 
Data were analyzed with Mann-whitney rank sum test and the results are expressed as median (IQR). 
a P < 0.01，b P < 0.001 vs CTL; ‘ P < 0.001 vs NDN. 
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3.2.2. Expression Profile in Plasma of Patients 
3.2.2.1. Cytokines and Chemokines 
As shown in Figures 3-1 and 3-2, plasma concentrations of inflammatory 
cytokines TNF-a, IL-6 and IL-18 and chemokine CCL2 of DN patients were 
significantly higher than control subjects (all P < 0.05). Adiponectin, IL-10, 
CXCL8, CXCL9 and CXCLIO concentrations in DN were significantly higher than 
in NDN and control subjects (all P < 0.05). The numerical results are summarized 
in Table 3-2. 
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Figure 3-1. Plasma concentrations of cytokines in type 2 diabetic patients and 
normal control subjects. The differences among groups were determined by 
Kruskal-Wallis test, followed by post hoc Dunn's multiple comparison test. * P < 
0.05，** 户 <0.01, <0.001. 
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Figure 3-2. Plasma concentrations of chemokines in type 2 diabetic patients 
and normal control subjects. The differences among groups were determined by 
Kruskal-Wallis test, followed by post hoc Dunn's multiple comparison test. * P < 
0.05, ** 户 <0.01, *** 户 <0.001. 
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Table 3-2. Plasma concentrations of chemokines and cytokines in type 2 diabetic 
patients and normal control subjects. 
Cytokine/ chemokine Group Median (IQR) (pg/mL) 
TNF-a CTL UD 
NDN UD 
DN 1.62 (0.00-2.19)* 
IL-ip CTL UD 
NDN UD 
DN UD 
IL-6 CTL UD 
NDN 2.25 (1.25-3.25) 
DN 2.50 (1.81-3.03)** 
IL-10 CTL UD 
NDN 1.81 (0.61-2.69) 
DN 2.58 (2.03-3.41)***,+ 
IL-12p70 CTL UD 
NDN UD 
DN UD 
IL-18 CTL 191 (132-276) 
NDN 199(154-269) 
DN 247 (171-303)* 
Adiponectin CTL 3200 (2200-4940) 
NDN 2230(1500-4290) 
DN 5930 (3720-8970)**.+++ 
CXCL8 CTL 2.29(1.72-2.88) 
NDN 3.24 (2.48-4.68)* 
DN 4.08 (3.68-6.57)***.+ 
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Table 3-2 (continued) 
Cytokine/ chemokine Group Median (IQR) (pg/mL) 
CXCL9 CTL 189 (153-273) 
NDN 244 (201-283) 
DN 425 (314-653)"*’++ 
CXCLIO CTL 345 (264-480) 
NDN 331 (282-488) 
DN 482 (389-606)*** 
CCL2 CTL 57.4 (37.5-83.5) 
NDN 58.7 (54.4-81.8) 
DN 71.0 (61.6-88.3)* 
CCL5 CTL 2590 (1360-5840) 
NDN 2230 (345-5620) 
DN 5040 (2030-6880) 
Results are expressed as median (IQR). The differences among groups were determined by 
Kruskal-Wallis test, followed by post hoc Dunn's multiple comparison test. * P < 0.05’ ** P < 0.01， 
*** /> <0.001 vs CTL; + •P < 0.05, 0.01,+++? <0.001 vs NDN. UD, not detected. 
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3.2.2.2. Soluble Costimulatory Molecules 
Figure 3-3 illustrates that the plasma sCTLA-4 was significantly 
downregulated, while sCD28 was significantly upregulated in DN compared with 
CTL (all P < 0.05). The numerical results are summarized in Table 3-3. 
5.2.2.3. Soluble Adhesion Molecules 
As shown in Figure 3-4, plasma concentrations of soluble adhesion 
molecules sICAM-1, sICAM-3, sE-selectin and sP-selectin of DN patients were 
significantly higher than those of control subjects (all P < 0.05). sPECAM-1 and 
sVCAM-1 concentrations in DN were significantly higher than in NDN and control 
subjects (all P < 0.05). The numerical results are summarized in Table 3-4. 
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Figure 3-3. Plasma concentrations of soluble costimulatory molecules in type 2 
diabetic patients and normal control subjects. The differences among groups were 
determined by Kruskal-Wallis test, followed by post hoc Dunn's multiple 
comparison test. * P < 0.05, ** P<0.01. 
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Table 3-3. Plasma concentrations of soluble costimulatory molecules of type 2 
diabetic patients and normal control subjects 
Soluble costimulatory Group Median (IQR) (ng/mL) 
molecules 
sCTLA-4 CTL 0.63 (0.51-0.89) 
NDN 0.42 (0.32-0.51) 
DN 0.39 (0.28-0.51)* 
SCD28 CTL 15.2 (10.6-17.5) 
NDN 14.30(12.6-19.8) 
DN 19.0(15.1-27.9)** 
sCD80 CTL 0.29 (0.16-0.47) 
NDN 0.19(0.12-0.26) 
DN 0.27 (0.20-0.41) 
SCD86 CTL 0.90 (0.59-1.20) 
NDN 1.00 (0.68-1.36) 
DN 0.56 (0.41-0.89) 
Results are expressed as median (IQR). The differences among groups were determined by 
Kruskal-Wallis test, followed by post hoc Dunn's multiple comparison test. * P < 0.05, ** p < 0.01 
vs CTL. 
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Figure 3-4. Plasma concentrations of soluble adhesion molecules in type 2 
diabetic patients and normal control subjects. The differences among groups 
were determined by Kruskal-Wallis test, followed by post hoc Dunn's multiple 
comparison test. * P < 0.05, *** P <0.001. 
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Table 3-4. Plasma concentrations of adhesion molecules in type 2 diabetic patients 
and normal control subjects. 
Soluble adhesion molecules Group Concentration (IQR) (ng/mL) 
si CAM-1 CTL 248 (206-309) 
NDN 298 (239-351) 
DN 317 (351-420)* 
sICAM-3 CTL 67.0(49.1-84.7) 
NDN 81.9(63.0-114) 
DN 93.5 (65.4-130)* 
sVCAM-1 CTL 498 (425-770) 
NDN 880 (640-1060)* 
DN 1020(795-1220)***’+ 
sPECAM-1 CTL 118 (108-128) 
NDN 125 (109-175) 
DN 164(127-191)***’+ 
sE-selectin CTL 32.2(27.9-47.1) 
NDN 64.1 (39.7-83.1) 
DN 69.0 (48.5-88.1)*** 
sP-selectin CTL 133 (113-176) 
NDN 202 (144-238)* 
DN 219(166-272)*** 
Results are expressed as median (IQR). The differences among groups were determined by 
Kruskal-Wallis test, followed by post hoc Dunn's multiple comparison test. * P < 0.05，*** P < 
0.001 vs CTL; + P < 0.05 vs NDN. 
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3.2.2.4. Correlations between Plasma Concentrations of Cytokines, 
Chemokines, soluble Costimulatory Molecules and soluble Adhesion 
Molecules and UACR in Patients 
Plasma concentrations of TNF-a, IL-6, IL-10, IL-18, CCL2, CXCL8, 
CXCL9, CXCLIO and adiponectin exhibited significantly positive correlations with 
UACR in DN patients but not in NDN patients (all P < 0.05, Table 3-5). Plasma 
concentrations of IL-18, CXCL9 and CXCLIO exhibited the most significant 
correlations with UACR (all P < 0.001). 
For plasma soluble costimulatory molecules, sCD28 and sCD80 were found 
to be positively correlated with UACR in DN patients but not in NDN patients; in 
contrast, CD86 showed a significantly negative correlation with UACR (all P < 0.05, 
Table 3-6). 
As shown in Table 3-7，there was a strong, positive correlation between 
plasma sVCAM-1 and UACR in DN patient, while plasma sP-selectin exhibited a 
significantly positive correlation with UACR in both NDN and DN patients (all P < 
0.05). 
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Table 3-5. Correlations between plasma cytokine and chemokine concentrations 
and UACR in NDN, DN and all type 2 DM patients. 
Cytokine/ Chemokine Group Spearman r P-value 
TNF-a NDN NA NA 
DN 0.296 0.046* 
NDN + DN NA NA 
IL-6 NDN 0.301 0.163 
DN 0.280 0.038* 
NDN + DN 0.239 0.038* 
IL-10 NDN 0.291 0.149 
DN 0.276 0.040* 
NDN + DN 0.255 0.016* 
IL-18 NDN -0.074 0.786 
DN 0.273 0.027* 
NDN + DN 0.361 <0.001*** 
Adiponectin NDN -0.333 0.385 
DN 0.287 0.048* 
NDN + DN 0.256 0.035* 
CXCL8 NDN -0.170 0.473 
DN 0.278 0.042* 
NDN + DN 0.247 0.029* 
CXCL9 NDN 0.012 0.950 
DN 0.245 0.049* 
NDN + DN 0.352 0.001*** 
CXCLIO NDN 0.274 0.159 
DN 0.318 0.009** 
NDN + DN 0.381 <0.001*** 
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Table 3-5 (continued) 
Cytokine/ Chemokine Group Spearman r P-value 
CCL2 NDN -0.176 0.370 
DN 0.271 0.031* 
NDN + DN 0.313 0.002** 
CCL5 NDN 0.192 0.328 
DN 0.125 0.328 
NDN + DN 0.274 0.009** 
Results were determined by Spearman's rank correlation coefficient; * P < 0.05，** P < 0.01，*** P < 
0.001. 
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Table 3-6. Correlations between plasma concentrations of soluble costimulatory 
molecules and UACR in NDN, DN and all type 2 DM patients. 
Soluble costimulatory Group Spearman r P-value 
molecules 
sCTLA-4 NDN -0.110 0.708 
DN 0.132 0.343 
NDN + DN -0.008 0.947 
SCD28 NDN 0.394 0.263 
DN 0.304 0.045* 
NDN + DN 0.361 0.005** 
sCD80 NDN -0.024 0.935 
DN 0.255 0.048* 
NDN + DN 0.266 0.020* 
sCD86 NDN 0.207 0.478 
DN -0.296 0.023* 
NDN + DN -0.348 0.003** 
Results were determined by Spearman's rank correlation coefficient; * P < 0.05, ** P < 0.01. 
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Table 3-7. Correlations between plasma adhesion molecule concentrations and 
UACR in NDN, DN and all type 2 DM patients. 
Soluble adhesion molecules Group Spearman r P-value 
sICAM-1 NDN 0.044 0.837 
DN 0.110 0.389 
NDN + DN 0.128 0.234 
sICAM-3 NDN 0.173 0.420 
DN 0.096 0.447 
NDN + DN 0.131 0.220 , 
sVCAM-1 NDN 0.134 0.532 
DN 0.412 <0.001*** 
NDN + DN 0.417 <0.001*** 
sPECAM-1 NDN 0.123 0.578 
DN 0.165 0.185 
NDN + DN 0.240 0.024* 
sE-selectin NDN 0.249 0.240 
DN 0.118 0.351 
NDN + DN 0.176 0.100 
sP-selectin NDN 0.422 0.040* 
DN 0.254 0.042* 
NDN + DN 0.342 0.001** 
Results were determined by Spearman's rank correlation coefficient; * P < 0.05, ** p < 0.01, *** P < 
0.001. 
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3.2.3. Effects of TNF-a and IL-18 on the ex vivo Production from Whole 
Blood of Patients 
The above findings prompted us to investigate the immunocompetence of 
leukocytes in the ex vivo production of inflammatory cytokines, chemokines and 
soluble costimulatory molecules from the whole blood of different patient cohorts. 
3.2.3.1. Ex vivo Production of Cytokines and Chemokines 
As shown in Table 3-8, TNF-a and IL-18 significantly induced the release 
of IL-6 and IL-10, and IL-18 also significantly induced CXCL8 in NDN and DN 
patients compared to the spontaneous production of chemokines/cytokines under 
basal condition (all P < 0.05). IL-18 suppressed CXCL9 release and TNF-a 
induced CXCLIO release significantly in DN patients (all P < 0.05). IL-18 
suppressed CCL2 and CCL5 release and TNF-a induced IL-18 and CXCL8 release 
significantly in all groups (all P < 0.05). 
The % increases of ex vivo production of IL-6, CXCL8, CXCLIO, CCL2 
and CCL5 after activation by TNF-a were significantly higher in both DN and NDN 
patients than in controls (all P < 0.05, Table 3-8). The % increases of ex vivo 
production of IL-18 induced TNF-a and CXCL8 were significantly increased in 
NDN patients than in controls (all P < 0.01). Significantly smaller % increases of 
65 
Chapter 3: Clinical Study on Patients with Diabetic Nephropathy 
ex vivo production of TNF-a-induced CXCL9 and IL-18 induced TNF-a and 
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3.2.3.2. Ex vivo Production of Soluble Costimulatory Molecules 
As implicated in Table 3-9, TNF-a and IL-18 significantly suppressed the 
ex vivo release of sCTLA-4 in control group, but increased the release of sCTLA in 
DN patients, compared to the spontaneous production under basal condition (all P < 
0.05). TNF-a and IL-18 induced sCD28 release significantly in DN patients (all P < 
0.05). TNF-a prompted sCD80 release significantly in all groups; in contrast, 
IL-18 suppressed sCD80 release significantly in DN patients (all P < 0.05). 
The % increases of ex vivo production of sCTLA-4 and sCD28 after 
activation by TNF-a and IL-18 were significantly higher in DN patients than 
controls (all P < 0.05, Table 3-9). Markedly smaller % increase of ex vivo 
production of TNF-a induced sCD80 was found in DN than in NDN and controls (all 
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3.2.4. Expression of Phosphorylated p38 MAPK, JNK and ERK in PBMC 
of Patients 
To characterize the intracellular activation mechanism for the release of 
cytokines and chemokines from PBMC, we investigated the phosphorylation of 
intracellular ERK and p38 MAPK and JNK in Th cells and monocytes. As shown 
in Tables 3-10 and 3-11, TNF-a could significantly induce the phosphorylation of 
ERK and p38 MAPK in monocytes of CTL and all DM patients, while IL-18 could 
significantly induce the phosphorylation of the 2 pathways in Th cells of all DM 
patients, respectively {P < 0.05). Table 3-10 shows that the % increase in 
IL-18-induced phosphorylation of ERK in Th cells of NDN and DN patients was 
significantly higher than that of CTL (尸 < 0.05). The % increase in TNF-a-induced 
phosphorylation of p38 MAPK in monocytes and IL-18-induced phosphorylation of 
p38 MAPK in Th cells and monocytes were significantly higher in NDN patients 
than in CTL (all ？ < 0.05，Table 3-11). However, the above % changes of 
phosphorylation of p38 MAPK were significantly lower in DN patients than NDN 
patients (P < 0.05). The % change of TNF-a and IL-18 induced phosphorylations 
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3.3. Discussion 
3.3.1. Cytokines, Chemokines and Diabetic Nephropathy 
Inflammation and deranged glucose and lipid metabolism have been 
implicated in the pathogenesis and pathophysiology of type 2 DM [Pickup, 2004]. 
Hypercytokinaemia and activated innate immunity may be the common antecedent 
of both type 2 DM and atherosclerosis [Pickup, 2004]. We have previously reported 
that elevation of proinflammatory cytokines could play an important 
immunopathological role in the chronic inflammation of chronic renal failure 
patients [Wong et al., 2007]. In the present study, we firstly showed that plasma 
concentrations of inflammatory cytokines TNF-a, IL-6, IL-18 and chemokine CCL2 
in DN patients but not in NDN patients were significantly higher than control 
subjects. Adiponectin, IL-10, CXCL8, CXCL9 and CXCLIO concentrations in DN 
were significantly higher than NDN patients and control subjects. Previous studies 
have also shown the elevation of inflammatory cytokines and chemokines in Type 2 
DM [Esposito et al., 2003; Nomura et al., 2000; Pickup, 2004]. Hyperglycemia could 
increase circulating cytokine concentrations by oxidative mechanisms, and this effect 
was more pronounced in subjects with impaired glucose tolerance [Esposito et al., 
2002; Morohoshi et al., 1996]. Adiponectin has been postulated to have pathological 
implications in diabetic nephropathy [Koshimura et al., 2004]. It is responsible for 
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glucose uptake, fatty acid catabolism, improving insulin sensitivity and mitigating 
vascular damage. Down-regulated plasma adiponectin in DM could indicate a poorer 
insulin sensitivity in the patients, while elevated plasma adiponectin in diabetic 
nephropathy might be due to renal insufficiency of excretion and/or increase in 
synthesis by the body so as to mitigate the intrarenal microvascular damage in the 
patients [Komaba et al., 2006; Koshimura et al., 2004]. 
In our present investigation, the striking findings were the significant and 
positive correlations for plasma concentrations of TNF-a, IL-6, IL-10, IL-18, CCL2, 
CXCL8, CXCL9, CXCLIO and adiponectin with severity of nephropathy in DN 
patients. Moreover, IL-18, CXCL9 and CXCLIO exhibited the most significant 
correlations with severity of nephropathy. Results therefore confirmed the above 
studied panel of inflammatory cytokines, chemokines and adiponectin but not IL-1(3, 
IL-12 and CCL5 were involved in the nephropathy related inflammation in type 2 
DM patients, and Thl related cytokine and chemokine IL-18, CXCL9 and CXCLIO 
might play a crucial role for the diabetic nephropathy. 
Elevated circulating TNF-a and IL-18, the upstream cytokines for Thl 
immunity, have been shown to be associated with diabetic nephropathy in previous 
reports [Fischer et al., 2005; Mahmoud et al., 2004; Wang et al., 2005]. In the present 
study, IL-18 has been shown to have strong correlation with severity of diabetic 
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nephropathy. Moreover, TNF-a is also a modulator of glucose metabolism by the 
direct induction of insulin resistance and downregulation of insulin receptor 
signaling [del Aguila et al., 1999]. In order to mimic the local Thl-mediated 
inflammatory reaction and the responsiveness of leukocytes upon activation in type 2 
DM patients, we studied the ex vivo production of cytokines and chemokines from 
TNF-a or IL-18 activated PBMC. In the presence of external stimuli, the % 
increases of ex vivo production of TNF-a induced IL-6, CXCL8，CXCLIO, CCL2 
and CCL5 were significantly higher in both DN and NDN patients than in controls 
(all P < 0.05). The % increases of IL-18 induced TNF-a and CXCL8 were 
significantly increased in NDN patients than in controls (P < 0.01). However, 
significantly less % increases of TNF-a induced CXCL9 and IL-18 induced TNF-a 
and CXCL8 were found in DN than NDN patients (all P < 0.05). Actually, 
previous study has also shown that type 1 DM patients did not express higher 
LPS-induced TNF-a, IL-1(3 and IL-6 levels than controls using whole blood assay 
[Araya et al., 2003]. The elevated TNF-a induced IL-6, CXCL8, CXCLIO, CCL2 
and CCL5 from leukocytes further indicated the aberrant production of the above 
inflammatory cytokine, chemokines for neutrophils (CXCL8), Thl lymphocytes 
(CXCLIO), macrophages (CCL2) and activated T lymphocytes (CCL5) in type 2 DM 
patients. It has been shown that CXCL8 increased in early stage of diabetic 
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nephropathy, and CCL2 increased in the advanced stage of the disease [Tashiro et al., 
2002]. 
3.3.2. Soluble Costimulatory Molecules and Diabetic Nephropathy 
Our group has previously reported aberrant production of plasma soluble 
costimulatory molecules in asthma [Ip et al., 2005; Ip et al” 2006; Wong et al., 2005] 
and SLE [Wong et al, 2005]. But for diabetic nephropathy, the expression of plasma 
sCTLA-4, sCD28’ sCD80 and sCD86 have not been well investigated. We should be 
the first group demonstrating that sCTLA-4 significantly decreased in DN and 
sCD28 significantly increased in DN compared with controls {P < 0.05)，and plasma 
sCD28 correlated positively and significantly with disease severity {P < 0.01). 
sCTLA-4 can be produced either by shedding of the membrane form or 
alternative mRNA splicing [Oaks et al” 2000]. sCTLA-4 mRNA has been shown to 
be constitutively expressed from non-stimulated T lymphocytes, and its expression is 
downregulated after activation; in addition, sCTLA-4 is proposed to have 
immunoregulatory properties in vitro [Oaks et al., 2000]. Downregulated plasma 
sCTLA-4 in diabetic nephropathy might reflect a downregulation of membrane 
CTLA-4 expression that indicated less inhibitory signals transduced for T 
lymphocyte activation. On the other hand, sCTLA-4 may act as a competitor of 
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CD28 to bind CD80 or CD86, and interfere with T lymphocyte activation. Hence, 
lower sCTLA-4 expression might give less interference to the B7:CD28 interaction 
and hence less suppression to the transduction of promotion signals for T cell 
activation. 
Similar to sCTLA-1, sCD28 can result from membrane shedding or 
alternative mRNA splicing [Magistreeli et al., 1999], but recent polymerase chain 
reaction (PCR) analysis has suggested that circulating sCD28 is more likely due to 
shedding of the membrane form [Hebbar et al., 2004]. Previous in vitro studies have 
shown that sCD28 could induce IL-6 and IFN-y expression from APC such as 
dendritic cells. Moreover, sCD28 could enhance T lymphocyte-mediated immunity 
against tumour and self-peptides, and protection against microbial and tumour 
challenge [Orabona et al., 2004]. Elevation of plasma sCD28 in diabetic nephropathy 
might result from an upregulation of membrane CD28 expression that indicated more 
promotion signals transduced for T lymphocyte activation. Nevertheless, the detailed 
immunopathological role of these plasma soluble costimulatory molecules in patients 
with diabetic nephropathy requires further in-depth investigation. 
Our ex vivo experiments also confirmed that sCTLA-4 expression was 
downregulated in PBMC after either TNF-a or IL-18 stimulation in control subjects. 
This result corresponded with a previous study showing that sCTLA-4 mRNA 
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expression was downregulated after activation [Oaks et al., 2000]. Both the ex vivo 
release of sCTLA-4 and sCD28 increased after TNF-a and IL-18 stimulations in DN 
patients and showed a significantly elevated % increases when comparing with 
control subjects. This suggested that there might be dysregulation of CTLA- and 
CD28-mediated costimulatory mechanisms for T lymphocyte activation during local 
Thl-mediated inflammatory reaction in diabetic patients with nephropathy. The ex 
vivo release of sCD80 was found to be elevated in all groups after TNF-a stimulation 
and in DN patients only after IL-18 stimulation, but the release showed a 
significantly lower % increase in DN patients compared with controls. In contrast, 
sCD86 could not be induced ex vivo in any groups. These results are similar to the 
observation in active SLE patients that were investigated by our group previously 
[Wong et al., 2005]. The underlying mechanism leading to lower ex vivo induction of 
sCD80 in diabetic nephropathy and how this was related to disease development in 
diabetic nephropathy remained unresolved. As membrane CD80 is expressed mainly 
on CD4+ Th cells and mCD86 is expressed mostly on CD8+ cytotoxic T 
lymphocytes [Abe et al., 1999], hence we postulated that mCD80 and mCD86 
possibly played different immunological roles and generate their soluble forms via 
distinct mechanisms. 
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3.3.3. Soluble Adhesion Molecules and Diabetic Nephropathy 
Leukocyte adhesion to endothelial cells and transmigration are controlled 
through the expression of adhesion glycoproteins on the endothelial and leukocyte 
surfaces. Soluble forms of these adhesion molecules commonly result from cell 
surface adhesion molecule shedding due to cell stimulation [Volin, 2005]. They may 
also result from de novo synthesis of truncated soluble forms of adhesion molecules 
[Volin, 2005] or viral infection [Sung et al., 2001]. Soluble adhesion molecules 
circulate in blood and hence their plasma concentrations are a surrogate marker of 
the cellular expression. We demonstrated that the plasma concentrations of all the 
analyzed soluble adhesion molecules sICAM-1, sICAM-3, sVCAM-1, sPECAM-1, 
sE- and sP-selectins were significantly higher in DN patients than in control subjects. 
The plasma concentrations of sVCAM-1 and sP-selectin in NDN patients were also 
markedly higher than in control subjects, while the level of sVCAM-1 in DN patients 
was even significantly higher than in NDN patients. 
The results of elevated sICAM-1 concurred with the data reported by Guler 
et al. [Guler et al., 2002]. Park et al. suggested that high glucose concentration could 
upregulate ICAM-1 protein and mRNA expression in mesangial cells and promote 
leukocyte adhesion by upregulating ICAM-1 possibly through osmosis and the 
protein kinase-C nuclear factor kappa B pathway [Park et al, 2000]. Besides, some in 
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vitro and in vivo studies proposed that high glucose or AGEs could activate 
macrophage that could in turn promote ICAM-1 expression on tubular cells and 
production of transforming growth factor (TGF)-pi [Chow et al, 2005]. Furthermore, 
recruitment of activated neutrophils in diabetic patients by ICAM-1 might contribute 
to capillary obstruction and vascular injury, thereby initiating or enhancing the 
degree of glomerular injury in DM patients [Guler et al., 2002]. 
ICAM-3 is a counter receptor to ICAM-1 and is constitutively expressed on 
the majority of infiltrating leukocytes in kidney [Knudsen et al, 1995]. Besides, 
ICAM-3 is highly expressed on the surface of resting T lymphocytes and can 
function as a costimulatory molecule during T lymphocyte activation [Bemey et al., 
1999，de Fougerolles et al., 1994; van Kooyk and Geijtenbeek, 2002]. It also assists 
the initial contact between APC and T lymphocytes [Montoya et al., 2002]. We have 
demonstrated for the first time that sICAM-3 was upregulated in diabetic 
nephropathy. Associating with existing evidence, it suggested that upregulation of 
ICAM-3 probably facilitated the initiation of the inflammatory response in diabetic 
nephropathy via leukocyte recruitment and activation. 
Activated endothelial cells are a major source of VCAM-1，which is shed 
from the cell surface into the circulation during endothelial activation or damage. 
Previous studies have reported increased plasma concentration of sVCAM-1 in type 
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1 and type 2 diabetic patients with nephropathy [Clausen et al., 2000; Murakami et 
al” 2001]. Our present results showed that plasma sVCAM-1 concentration was 
highest in DN patients and correlated strongly with UACR. The plasma sVCAM-1 
concentration in NDN patients was significantly lower than in DN patients but higher 
than in control subjects. These results suggested that the plasma sVCAM-1 
concentration might be associated with vascular injury in DM and diabetic 
nephropathy. Simultaneously, significantly positive correlation between plasma 
sVCAM-1 and UACR revealed that severity of nephropathy increased with VCAM-1 
expression, proposing sVCAM-1 might be useful in monitoring diabetic patients, 
especially those with nephropathy. Furthermore, previous studies reported that 
plasma sVCAM-1 significantly correlated with plasma 7-ketocholesterol level, which 
was a major cholesterol auto-oxidation product [Murakami et al., 2001]. Taking the 
data together, we suggested that sVCAM-1 could be a good indicator of oxidative 
stress and intrarenal vascular inflammation in diabetic nephropathy. 
Our study was the first study that reported a relationship between 
PEC AM-1 and nephropathy in type 2 diabetic patients. Its role in the pathogenesis of 
nephropathy remains enigmatic. PECAM-1 expression is high in kidney [Wang et al., 
2003] and on platelets, monocytes, neutrophils, selected T lymphocyte subsets and 
on endothelial cell intercellular junctions [Newman, 1997]. Recently, soluble 
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PEC AM-1 has been shown to increase in patients with inflammation and heart 
failure [Figarella-Branger et al., 2006; Serebruany et al., 1999]. It is possible that an 
increase in PECAM-1, which mediates both leukocytes and platelet-endothelium 
interactions and leukocyte transendothelial migration, facilitates thrombus formation 
[Ilan and Madri, 2003; Soeki et al., 2003]. Moreover, PECAM-1 has been observed 
to be shedded by metalloproteinase-dependent cleavage of the cytoplasmic tail of the 
membrane form during endothelial cell apoptosis [Ilan et al” 2001]. Thus, 
upregulation of soluble PECAM-1 may reflect the degree of microvascular injury 
and endothelial cell apoptosis in diabetic nephropathy. 
E- and P-selectins are leukocyte adhesion molecules expressed on the 
vascular endothelial cells. We demonstrated a significant elevation in the plasma 
concentrations of sE- and P-selectins in DN patients, consistent with the finding of 
increased E- and P-selectin expression along the glomerular capillaries and the 
peritubular capillaries in the interstitium of patients with diabetic nephropathy 
[Hirata et al, 1998]. These results suggested that E- and P-selectins might play a key 
role in leukocyte infiltration into the renal interstitium in diabetic nephropathy. In 
addition, elevated sP-selectin expression could also reflect platelet activation. 
P-selectin on platelet could assist the recruitment of monocyte-derived microparticles 
that enhanced thrombosis [Andre et al., 2000]. Hence, we postulated that P-selectin 
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might be also critical in causing microvascular damage in the kidney of diabetic 
nephropathy patients. In addition, its upregulation could reflect the severity of 
nephropathy as we demonstrated a significantly positive correlation between plasma 
sP-selectin concentration and UACR in DN patients. 
To conclude, ICAM-1, ICAM-3，VCAM-1, PECAM-1, E- and P-selectins 
appears to be a critical promoter of microvascular injury in diabetic nephropathy by 
facilitating kidney leukocyte recruitment and activation and capillary thrombosis. 
3.3.4. Intracellular Signaling and Diabetic Nephropathy 
To further elucidate the abnormalities of the activation of leukocyte subsets 
in type 2 DM patients, we have investigated the activation of intracellular signaling 
molecules in TNF-a and IL-18 treated lymphocytes and monocytes. Results 
indicated that the % increases in IL-18-induced phosphorylation of ERK in Th cells 
of NDN and DN patients were significantly higher than controls. As ERK is 
responsible for cell proliferation, transformation, differentiation and cytokine 
production [Chambard et al, 2006; Wong et al., 2005; Wong et al., 2005], the 
increased activation of ERK in Th cells in NDN and DN patients implied 
hyper-activation of Th cell-mediated inflammation in type 2 DM and diabetic 
nephropathy. Moreover, the % increases in TNF-induced phosphorylation of p38 
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MAPK in monocytes and IL-18-induced phosphorylation of p38 MAPK in Th cells 
and monocytes were significantly higher in NDN patients than in controls. JNK 
also showed similar activation pattern upon TNF-a and IL-18 stimulation. p38 
MAPK and JNK are both responsible for the regulation of stress response and 
inflammation of the pathology of chronic inflammation, heart disease, stroke, the 
debilitating effects of diabetes mellitus, and the side effects of cancer therapy by the 
upregulation of inflammatory cytokines and regulation of apoptosis of different 
leukocytes, especially macrophages [Hirosumi et al., 2002; Kyriakis and Avruch, 
2001; Viallard et al., 1999]. Previous study indicated that glucose could regulate 
CXCL8 production in aortic endothelial cells through activation of p38 MAPK 
pathway in diabetes [Srinivasan et al., 2004]. Therefore, our results of the 
hyper-activation of p38 MAPK in monocytes and Th cells further implicated the 
activated monocytes and Th cells mediated inflammation in type 2 DM patients. 
Although our results showed significant % change of phosphorylation post 
TNF-a and IL-18 activation in PBMC among groups, the magnitude of the detected 
mean fluorescence intensities and % change were not large. This might be due to 
high background during flow cytometric measurement and the applied antibodies' 
efficiency of entering permeabilizaed cells, affinity and specificity. Nevertheless, the 
significance of our results might still provide biochemical basis for intracellular 
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signal transduction of type 2 DM and diabetic nephropathy and targeting them for 
treatment strategy of type 2 DM [Kaneto et al, 2004]. 
In conclusion, our results revealed the correlation of the elevated 
inflammatory molecules with the severity of diabetic nephropathy and exemplified 
the potential roles of TNF-a and IL-18 in the exacerbation of inflammatory reactions. 
The above immunological mechanisms probably involved the abnormal activation of 
p38 MAPK, INK and ERK in activated lymphocytes and monocytes. The results of 
this clinical study might therefore provide further biochemical basis for the 
elucidation of the pathological mechanisms of diabetic nephropathy and the 
development of novel therapeutic approach (e.g. inhibitors for signaling molecules) 
in the treatment and management of type 2 DM and its associated inflammation. 
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Chapter 4 
In Vitro Study on the Signal Transduction 
Mechanism Regulating the Expression of CCL2 
and Cell Surface Adhesion Molecules in 
Tumour Necrosis Factor (TNF)-a-Stimulated 
Human Proximal Tubular Epithelial HK-2 Cells 
4.1. Introduction 
Diabetic nephropathy is one type of chronic kidney diseases (CKD). CKD 
is characterized by a gradual and usually permanent loss of kidney function, which 
may progress to ESRD. 
There is growing evidence that macrophages and T-lymphocytes infiltrate 
into glomeruli and interstitium of the kidney during the progression of CKD, 
resulting in tubulointerstitial changes and nephritis [Nikolic-Paterson et al., 2001]. 
These infiltrating cells accelerate tissue damage via the production of 
proinflammatory cytokines and growth factors such as tumor necrosis factor (TNF)-a 
and transforming growth factor (TGF)-P [Sean Eardley et al., 2005]. Nevertheless, 
the intimate mechanism underlying macrophage infiltration is not fully clarified. 
Proximal tubular epithelial cells (PTEC) are reported to play a central role in 
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producing cytokines, chemokines and cell adhesion molecules for the recruitment, 
retention and activation of these infiltrating cells at the inflammatory sites [Daha et 
al., 2000; van Kooten et al., 1999]. 
TNF-a has attracted most attention among all proinflammatory cytokines 
related to kidney disease as it acts as a mediator of diverse inflammatory reactions, 
contributing to direct renal lesion. TNF-a is synthesized by monocytes and 
macrophages [Jaattela, 1991], as well as intrinsic resident renal cells, such as 
endothelial, mesangial, glomerular and tubular epithelial cells [Baud et al., 1992]. 
There is much evidence that serum and urinary TNF-a levels are significantly 
up-regulated in various renal diseases such as diabetic nephropathy (DN) [Navarro 
and Mora-Fernandez C, 2006], which is the leading cause of ESRD and accounts for 
approximately two-thirds of all ESRD cases [NKF KDOQI and NIH/ NIDDK, 2001]. 
Urinary TNF-a concentration increases independently to serum TNF-a concentration 
[Mora and Navarro, 2004], suggesting that local inflammation may occur via the 
intrarenal production of TNF-a by renal cells. 
It is very likely that during tubulointerstitial injury, leukocytes are firstly 
attracted to inflamed renal tissue by chemokines. Subsequently, they accumulate and 
adhere to tubular epithelial cells with the facilitation of cell surface adhesion 
molecules. CCL2, namely monocyte chemoattractant protein-1 (MCP-1), is a highly 
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specific chemotactic factor for macrophages and T-lymphocytes [Gerard C and 
Rollins, 2001]，and widely produced by various cell types such as mesangial cells, 
endothelial cells and epithelial cells [Ip et al., 2006; Ha et al., 2002; Volk et al., 2000]. 
CCL2 is found to be up-regulated in many renal diseases [Eardley et al., 2006; Rovin 
et al., 1996], including DN [Banba et al., 2000]. Intercellular adhesion molecule-1 
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), belonging to the Ig 
superfamily, are the most important adhesion molecules for leukocyte adhesion and 
migration into inflammatory sites. They are transmembrane glycoproteins and 
constitutively expressed on leukocytes, endothelial cells, fibroblasts and epithelial 
cells [Petruzzelli et al., 1999; Ulbrich et al., 2003]. They are found to be enhanced in 
different types of chronic renal failure [Musial et al., 2005; Suliman et al., 2006]. All 
the above inflammation-related molecules may play a crucial role in the local 
intrarenal inflammation by promoting accumulation and transmigration of 
inflammatory cells. 
Mitogen-activated protein kinases (MAPKs) are a family of 
serine-threonine kinases, participating in many cellular responses such as 
inflammation, cell growth, differentiation and apoptosis [Cuschieri et al., 2005]. 
Intracellular p38 MAPK, c-Jun N-terminal kinases (JNK) and extracellular 
signal-regulating kinases (ERK) are three well characterized subtypes of MAPKs and 
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all expressed in the kidney [Masaki et al., 2003; Peng et al., 2002; Stambe et al., 
2003]. Although TNF-a has been reported to activate these MAPKs, little is known 
about the MAPK signaling pathways regulating the expression of CCL2, ICAM-1 
and VCAM-1 expression ofPTEC. 
In this study, we investigated the expression profile of cytokines and 
chemokines of human PTEC, Human Kidney-2 (HK-2) cells upon TNF-a activation 
and the in vitro effect of TNF-a on the CCL2, ICAM-1 and VCAM-1 expression of 
the cells in order to understand the recruitment and migration of leukocytes in 
inflamed renal tubule. In addition, we elucidated the underlying intracellular 
mechanisms involving the activation of p38 MAPK, JNK and ERK in regulating 
TNF-a-induced CCL2, ICAM-1 and VCAM-1 expression of HK-2 cells. 
4.2. Results 
4.2.1. Expression Profile of Cytokines and Chemokines of TNF-a-activated 
HK-2 Cells 
Figure 4-1 illustrates the cytokine and chemokine expression profile of 
HK-2 cells without or with TNF-a (20 ng/mL) activation for 24 hours, indicating 
that TNF-a could activate HK-2 cells to markedly induce the release of chemokine 
CCL2. 
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Figure 4-1. Representative profile of the release of cytokines from 
TNF-a-activated HK-2 cells. HK-2 cells (3 x 10^  cells/mL) were treated with or 
without TNF-a (20 ng/mL) for 24 h. Cell-free culture supernatant was then 
harvested and 79 different cytokines and chemokines in culture supernatant were 
semiquantitated using antibody-based RayBio human cytokine array V. Positive 
and negative controls were designated at (la, lb, Ic, 1 d，8j, 8k) and (le, If, 1 g, 
8i)，respectively. Triplicate experiments were performed with essentially identical 
results. Table listed the format of antibodies on the cytokine membrane array. 
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4.2.2. TNF-a Upregulated CCL2, ICAM-1 and VCAM-1 Expression in HK-2 
Cells 
As shown in Figure 4-2，non-stimulated HK-2 cells expressed CCL2 and 
ICAM-1 constitutively but relatively little VCAM-1. Their expression was 
significantly enhanced by TNF-a in a dose-dependent manner (all P < 0.05). 
( A ) CCL2 ( B ) ,CAM.1 
150-, … 1251 
*** I 
125- """" 100- ^ I 




0 1 1 1 1 1 1 1 1 —1 1 
0 10 20 30 40 50 0 10 20 30 40 50 
TNF-a (ng/mL) TNF-a (ng/mL) 
( C ) 5 VCAM-1 
4- T 
oH 1 1 1 1 1 
0 10 20 30 40 50 
TNF-a (ng/mL) 
Figure 4-2. Effects of TNF-a on CCL2, ICAM-1 and VCAM-1 Expressions in 
HK-2 Cells. HK-2 cells (3 x 10^  cells/mL) were incubated with TNF-a (0 - 40 
ng/mL) for 24 hours. (A) CCL2 concentration in culture supernatant was analyzed 
by ELISA. (B) Cell surface expressions of ICAM-1 and (C) VCAM-1 were 
analyzed by flow cytometry. Results are expressed as mean ± SEM of triplicate 
experiments. *P < 0.05, **P < 0 . 0 1 ， < 0.001 vs control. 
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4.2.3. TNF-a Activated the p38 MAPK, JNK and ERK Signaling Pathways in 
HK-2 Cells 
The representative flow cytometric histograms in Figures 4-3A，B and C 
illustrate the upregiilated expressions of phosphorylated p38 MAPK, JNK and ERK 
after TNF-a stimulation for 15 minutes in the HK-2 cells. The activities of the three 
MAPK signaling pathways peaked at 15 minutes (all P < 0.05 vs control) but 
declined to basal level at 30 minutes (Figures 4-3D, E and F). 
4.2.4. Cytotoxicity of MAPK Inhibitors 
The cytotoxicity of MAPK inhibitors was studied with MTT assay. The 
applied maximal effective doses were judged at which the cell viability should 
maintain at about 80 %. The maximal effective doses of SB203580, SP600125 and 
PD98059 used were 50, 5 and 50 |aM respectively (Figure 4-4A, B and C). Since 
DMSO (1 |iL/mL) acted as a medium vehicle for SP600125 and PD98059, its 
cytotoxicity on the cells was also determined. It was found that 1 }iL/mL of DMSO 
did not cause significant cytotoxic effect on the cells (Figure 4-4D). 
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Figure 4-3. Effects of TNF-a on intracellular MAPK signaling pathways. 
HK-2 cells (3 x lO^cells/mL) were incubated with TNF-a (20 ng/mL) for 15 or 30 
minutes. Intracellular expressions of phosphorylated p38 MAPK, JNK and ERK 
were analyzed by flow cytometry. Representative histograms illustrate the 
intracellular expression of phosphorylated (A) p38 MAPK, (B) JNK and (C) ERK 
after 15-minute TNF-a stimulation in HK-2 cells. The gray outlined peak and the 
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black outlined peak represent the non-stimulated cell populations stained with 
anti-mouse IgGi isotype control and anti-human phospho-p38 MAPK, JNK or 
ERK monoclonal antibodies respectively. The solid peak represents the 
TNF-a-stimulated cell population stained with anti-human phospho-p38 MAPK, 
JNK or ERK monoclonal antibodies. Each histogram represents 3 x 10^  cells. 
Figures (D), (E) and (F) present the quantitative expression of phosphorylated p38 
MAPK, JNK and ERK respectively at 0, 15 and 30 minutes in terms of MFI. 
Results are expressed as mean 士 SEM of triplicate experiments. *P < 0.05 vs 
control. 
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Figure 4-4. Cytotoxicity of MAPK inhibitors on HK-2 cells. HK-2 cells (3 x 10^  
cells/mL) were incubated with (A) SB203580, (B) SP600125, (C) PD98059 and 
(D) DMSO at various concentrations for 24 hours. Cell viability was then 
determined with MTT assay. The results are presented as mean 士 SEM of triplicate 
experiments. 
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4.2.5. Effects of p38 MAPK, JNK and ERK Inhibitors on TNF-a-induced 
Expressions of CCL2，ICAM-1 and VCAM-1 
All MAPK inhibitors suppressed the TNF-a-induced CCL2 expression in 
HK-2 cells in a dose-dependent manner. Maximal dose of SB203580 completely 
suppressed the TNF-a-induced CCL2 expression while maximal doses of SP600125 
and PD98059 suppressed about 50 % of the expression (Figures 4-5A, D and G; all 
P < 0.05). TNF-a-induced ICAM-1 expression was diminished by all MAPK 
inhibitors dose-dependently and reduced about 50 % at maximum doses (Figures 
4-5B, E and H; all P < 0.05). Although maximum doses of SB203580 and PD98059 
could completely inhibit VCAM-1 expression (all P < 0.001), only the suppressive 
effect of PD98059 showed a dose-dependent manner. SP600125 alone could 
dose-dependently enhance VCAM-1 expression on non-stimulated HK-2 cells {P < 
0.05), but did not significantly affect the TNF-a-induced VCAM-1 expression 
(Figure 4-5C, F and I). 
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Figure 4-5. Effects of MAPK inhibitors on TNF-a-induced CCL2, ICAM-1 
and VCAM-1 expression. HK-2 cells (3 x 10^  cells/mL) were pre-incubated with 
(A, B and C) SB203580 (10 — 50 fiM)，（D，E and F) SP600125 (1 - 5 |iM) and (Q 
H and I) PD98059 (10 - 50 |LIM) for 1 hour and then incubated without or with 
TNF-a (20 ng/mL) for 24 hours. CCL2 expression was analyzed by ELISA, while 
ICAM-1 and VCAM-1 expression was analyzed with flow cytometry. Results are 
presented as mean 士 SEM of triplicate experiments. < 0.05, **P<0.0\ , ***P< 
0.001 vs TNF-a-stimulated HK-2 cells without MAPK inhibitors. <0.05 vs 
non-stimulated HK-2 cells (CTL). CTL, control; SB, SB203580; SP, SP600125; 
PD, PD98059. 
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4.3. Discussion 
Inflammation-associated tubulointerstitial alteration is a common 
degenerative characteristic of CKD. Activated PTEC are found to be capable of 
overexpressing cytokines, chemokines and cell adhesion molecules for mediating 
leukocyte infiltration into renal tissue [Daha et al., 2000; van Kooten et al., 1999]. 
TNF-a is a potent inflammatory component in renal diseases and its production is 
positively correlated with disease severity [Mora and Navarro, 2004]. It can induce 
apoptosis, chemotaxis, and modulate the secretion of other inflammatory mediators 
such as IL-6 in various cell types [Atkins et al., 1996]. In this study, we demonstrated 
that TNF-a could markedly induce CCL2 production and cell surface expression of 
ICAM-1 and VCAM-1 in HK-2 cells dose-dependently, implying the association of 
these inflammatory molecules with the pathogenesis and severity of tubulointerstitial 
impairment in CKD. 
Our results concurred with previous studies that PTEC could synthesize 
CCL2 following stimulation by cytokines and proinflammatory mediators like 
TNF-a and IL-la [Prodjosudjadi et al, 1995; Wang et al., 1997]. Besides its 
chemotactic property for mononuclear cell infiltration, CCL2 can also induce the 
release of lysosomal enzymes, generation of superoxide anions, and expression of 
proinflammatory cytokines from macrophages [Baggioli et al., 1994; Rollins, et al” 
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1991] that cause manifestation of intrarenal inflammation. 
Consistent with our finding, it has been also reported that ICAM-1 and 
VCAM-1 expression on proximal tubular epithelial cells could be induced by TNF-a 
[Weinreich et al., 2001]. ICAM-1 can bind to lymphocyte function-associated 
antigen-1 (LFA-1)，macrophage antigen-1 (Mac-1), fibrinogen, hyaluronan and 
CD43, while VCAM-1 can bind to very late antigen-1 (VLA-4) [Ulbrich et al, 2003]. 
All these ligands are widely distributed on leukocytes. The interaction of adhesion 
molecules with these ligands is a critical step for the migration of leukocytes from 
blood to inflammatory sites. 
The intracellular signaling mechanisms regulating the TNF-a-induced 
CCL2, ICAM-1 and VCAM-1 expression in PTEC are not completely understood. 
The signal transduction cascades are so complicated that they finely control gene 
expressions via phosphorylation of various protein kinases and target proteins upon 
various extracellular stimulations, and elicit precise and diversified cellular responses 
[Pouyssegur et al., 2002]. In this study, we have studied three well-characterized 
MAPK cascades: p38 MAPK, JNK and ERK pathways. p38 MAPK and JNK are 
important modulators of cell apoptosis, differentiation, degranulation and synthesis 
of inflammatory components; meanwhile, ERK is essential for cell proliferation and 
differentiation [Awazu et al., 2002]. We have demonstrated that TNF-a stimulation 
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could activate all the three MAPKs in HK-2 cells. To further elucidate the role of 
theses pathways in mediating the expression of CCL2, ICAM-1 and VCAM-1 
induced by TNF-a, we utilized specific p38 MAPK, JNK and ERK inhibitors, 
namely SB203580, SP600125 and PD98059, respectively. 
For the TNF-a-induced CCL2 expression, inhibition of p38 MAPK 
suppressed the expression to the basal level, while inhibition of JNK and ERK 
suppressed only about 50 %. This suggested that TNF-a up-regulated CCL2 
expression via the activation of p38 MAPK and at least in part via the activation of 
JNK and ERK. There is increasing evidence for a crosstalk or interaction between 
discrete intracellular MAPK signaling pathways [Tsang et al., 2005; Wong et al., 
2004]. MAPKs such as p38 MAPK have also been shown to be required for nuclear 
factor-kappaB (NF-KB)-dependent gene expression [Carter et al., 1999]. Therefore, 
this crosstalk might account for the partial inhibitory effect of JNK and ERK 
inhibitors even p38 MAPK inhibitor alone could present complete suppression on 
elevated CCL2 expression. Concurrently, either inhibition of p38 MAPK, JNK or 
ERK could partially diminish the induced ICAM-1 expression by TNF-a. These 
results indicated that all the three MAPK pathways were partly but not 
predominantly involved in the induction. On the other hand, TNF-a-induced 
VCAM-1 expression was dampened strongly by blocking p38 MAPK and ERK. Our 
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results showed that treating HK-2 cells with SP600125 alone prompted the VCAM-1 
expression. Previous studies have reported that JNK inhibition enhanced VCAM-1 
expression in human chondrosarcoma cells and gingival fibroblasts and exhibited an 
additive effect with TNF-a on VCAM-1 expression [Hosokawa et al., 2006; Ju et al., 
2002]. However，in our study, JNK inhibition did not show such significant additive 
effect on VCAM-1 expression in TNF-a-stimulated HK-2 cells. Therefore, we might 
conclude that the induction of VCAM-1 expression by TNF-a in HK-2 cells was 
dependent of the activation of p38 MAPK and ERK but not JNK. Further 
investigation is needed for other possible involved signaling pathways, such as Janus 
kinase (JAK)-signal transducers and activators of transcription (STAT) and 
AKt-Phosphoinositide 3-kinases (PI3K), which take part in the regulation of cellular 
responses to cytokines. 
In our study, HK-2 cells, instead of primary PTEC cells, were used as a 
model to demonstrate the proinflammatory action of TNF-a in human proximal 
tubule during inflammation, because cell line was more standardized and 
homogenous and easier to manipulate. We found that TNF-a could exaggerate the 
expression of CCL2, ICAM-1 and VCAM-1, which were thought to play a critical 
role in the recruitment and firm adhesion of infiltrating cells especially macrophages 
and lymphocytes at the inflamed kidney tissue. Moreover, our results revealed the 
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participation of p38 MAPK, JNK and ERK, at least in part, in the up-regulation of 
CCL2 and ICAM-1 expression induced by TNF-a; nevertheless, only p38 MAPK 
and ERK but not JNK were involved in the VCAM-1 overexpression. Our findings 
could expand our understanding in the intracellular signaling mechanisms regulating 
the induction of CCL2, ICAM-1 and VCAM-1 expression by TNF-a in human 
PTEC. These inflammatory molecules and underlying intracellular signaling 
molecules are potentially useful therapeutic targets for nephritis. 
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Chapter 5 
Conclusion and Future Prospects 
1.1 Conclusion 
In our present project, we have demonstrated that diabetic nephropathy is 
an immunopathological condition involving aberrant expression of cytokines, 
chemokines, costimulatory molecules and adhesion molecules in plasma and Thl 
immune deviation, the summary of which and the possible immune cells involved are 
depicted in Figure 5-1. 
Our findings implicated the inflammatory process of diabetic nephropathy 
involved a complex network of cytokines and chemokines. Elevated cytokines and 
chemokines could play crucial roles in diabetic nephropathy via activation, 
recruitment and trafficking of leukocytes, such as neutrophils, Thl lymphocytes and 
macrophages to inflammatory sites. They positively correlated with UACR, 
suggesting that they might be potential markers for screening the severity of 
nephropathy. 
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Figure 5-1. A schematic diagram illustrating the aberrant expression of 
cytokines, chemokines, costimulatory molecules and adhesion molecules in the 
plasma of NDN and DN groups, compared with CTL group, and the possibly 
involved immune cells. Those inflammatory molecules positively correlated with 
UACR are shown in red. Significant up-regulation and down-regulation of the 
expression, compared with CTL group, are shown with | and | respectively (all P < 
0.05). Significant up-regulation of the expression, compared with both CTL and 
NDN groups, is shown with f t (all P < 0.05). 
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Besides, our results showed that diabetic nephropathy might be related to 
dsyregulation of T lymphocyte activation due to aberrant production of soluble 
costimulatory molecules. Since the CD28/CTLA-4:CD80/CD86 costimulatory 
pathway regulates activation, differentiation and chemotaxis of T lymphocytes, the 
upregulation of sCD28 and downregulation of sCTLA-4 in diabetic nephropathy are 
likely to be influenced by the aberrant production of cytokines and chemokines for 
the induction of Thl immune response. 
Simultaneously in our study, upregulations of all investigated adhesion 
molecules were demonstrated in diabetic nephropathy, which were involved in the 
attachment and migration of leukocytes to interacting cells in inflamed renal tissue. 
We have discovered new striking findings of markedly elevated plasma sICAM-3 
and sPECAM-1 in diabetic nephropathy; in addition, sVCAM-1 and sP-selectin were 
also found to be markedly increased and have a strongly positive correlation with 
UACR. This concluded that upregulation of these adhesion molecules could 
accelerate microvascular inflammation and endothelial damage, possibly through 
platelet activation and thrombosis, in diabetic nephropathy. Moreover, since they 
increased with disease severity, this provided new postulates for potential surrogate 
markers of diabetic nephropathy. However, further elucidation of their roles and 
functions, such as investigating their expression in renal tissue of patients or 
109 
Chapter 5: Conclusion & Future Prospects 
undergoing in vitro experiments with renal cell-lines, are required. 
In the whole blood assay, we have demonstrated that the leukocytes of 
diabetic patients without or with nephropathy showed abnormal immune response 
upon TNF-a and IL-18 stimulations exemplified by the aberrant ex vivo production 
of inflammatory molecules from leukocytes under stimulations. These results could 
provide clues for the potential roles of TNF-a and IL-18 in the exacerbation of 
inflammatory reactions at the local inflamed kidney tissue. 
In the intracellular signaling analysis, our findings elucidated that increased 
activations of ERK in Th cells, p38 MAPK and JNK in monocytes and Th cells in 
type 2 DM patients indicated hyper-activation of monocyte- and Th cell-mediated 
inflammation in type 2 DM. The activation of these signaling pathways might be 
responsible for the upregulation of inflammatory molecules that participated in the 
immunopathogenesis of DM and diabetic nephropathy. 
Although the cause-effect relationships of these inflammatory phenomena 
with type 2 DM and diabetic nephropathy remain undetermined from the present 
results, additional studies can certainly help elucidating the distinct roles of different 
inflammatory molecules and their interactions that may underlie the 
immunopathological mechanisms of these diseases. 
Our in vitro study of TNF-a-activated HK-2 cells simultaneously deepened 
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our understanding on the inflammatory mechanism in inflamed renal tubule of 
patients with nephritis. We have demonstrated that TNF-a could induce CCL2, 
ICAM-1 and VCAM-1 via the activation of p38 MAPK, JNK and ERK signaling 
pathways, suggesting that macrophage and lymphocyte infiltration was a critical 
pathogenic mechanism of tubulointerstitial injury in nephritis. Nevertheless, further 
studies are required so as to investigate more inflammatory parameters and signaling 
pathways involved in tubular damage during intrarenal inflammation. 
1.2 Future Prospects 
We are going to collect more clinical information of the patients and 
healthy controls such as their systolic and diastolic blood pressures, which reflect the 
state of hypertension, and HbAic, which is the glycosylated hemoglobin in blood and 
its level reflects the average blood glucose level over time, differing from plasma 
glucose level that fluctuates over the time of a day. Hence, we can further investigate 
the correlation of these parameters with the plasma concentration of inflammatory 
mediators in DM and diabetic nephropathy. 
In addition, before we can target the elevated inflammatory parameters as 
potential diagnostic markers of diabetic nephropathy, we need to consider their 
111 
Chapter 5: Conclusion & Future Prospects 
urinary level as well as their plasma level. We should first confirm an inflammatory 
parameter is significantly augmented in the plasma and urinary concentrations and 
correlated with UACR. Subsequently, if there is no significant correlation between 
the plasma and urinary concentrations, this implied that the targeted parameter can be 
produced locally within the kidney and may be a good predictor of the degree of 
diabetic nephropathy. This can also give us insights into the development of specific 
anti-inflammatory therapeutic agents for DM and diabetic nephropathy. 
In recent years, development of inhibitors targeting at MAPK is becoming 
an attractive strategy for treating inflammatory diseases. Clinical trials of testing 
orally active p38 MAPK inhibitors for treating rheumatoid arthritis and Crohn's 
disease in humans are ongoing [Ding, 2006; Schreiber et al., 2006]. A number of 
JNK inhibitors have demonstrated the efficacy of ameliorating some symptoms of 
arthritis in animal models [Bogoyevitch et al., 2004]. Although ERK inhibitors have 
not been tested yet for treating inflammatory diseases in human and animal models, 
some of them have been targeted as potent anti-cancer drugs and reached the clinical 
trial stage [Kohno and Pouyssegur, 2006]. Till now, there is no clinical investigation 
on the therapeutic efficacy of MAPK inhibitors to type 2 DM and diabetic 
nephropathy in humans, but p38 MAPK inhibitors have been found to have 
beneficial cardiovascular effects in diabetic rats [Riad et al., 2006; Medicherla et al., 
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2006]. Besides p38 MAPK, our study also provided evidence of the involvement of 
JNK and ERK in the pathogenesis of DM and diabetic nephropathy. The feasibility 
of applying the inhibitors of these signaling molecules as therapeutic agents is still 
needed to be clarified. 
In our clinical study, we were unable to conclude which groups of patients 
have higher susceptibility to diabetic nephropathy. In order to find the answer, we 
will need to extract the genomic DNA from the PBMC or renal tissues of healthy 
controls and patients with diabetic nephropathy. Then, genotyping for the 
polymorphism of a specific gene will be performed using a PCR—restriction fragment 
length polymorphism method [Wilson et al., 1992]. The frequencies of allele and 
genotype of different cohorts will be finally compared. Previously, Wang et al. 
reported that the GG genotype of TNF-a-G-308A polymorphism might interact with 
obesity to increase the risk of nephropathy in Chinese type 2 diabetic patients [Wang 
et al., 2005]. Nevertheless, replication of these analyses in different ethnic groups is 
needed. In addition, further studies are required to examine the structure and function 
of the suspected genes, as well as their interactions with other genetic and 
environmental factors in disease development, so as to resolve the question of 
susceptibility to DM and diabetic nephropathy. 
We sincerely hope that our findings can ultimately contribute to the 
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potential development of novel anti-inflammatory therapeutic agents for the 
treatment of type 2 DM and diabetic nephropathy, which can certainly benefit 
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